



(51) International Patent Classification:

C07D 263/40 (2006.01) *A61K 31/421* (2006.01)
C07D 263/46 (2006.01) *A61P 31/04* (2006.01)

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

(21) International Application Number:

PCT/US2017/048036

Published:

— *with international search report (Art. 21(3))*

(22) International Filing Date:

22 August 2017 (22.08.2017)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/378,174 22 August 2016 (22.08.2016) US

(71) Applicant: NORTH CAROLINA STATE UNIVERSITY [US/US]; 1021 Main Campus Drive, 2nd Floor, Raleigh, North Carolina 27606 (US).

(72) Inventors: PIERCE, Joshua G.; 1021 Main Campus Drive, 2nd Floor, Raleigh, North Carolina 27606 (US). EDWARDS, Grant A.; 3952 Wendy Lane, Raleigh, North Carolina 27606 (US).

(74) Agent: ZUCCHERO, Anthony J. et al.; MEUNIER CARLIN & CURFMAN LLC, 999 Peachtree St. NE, Suite 1300, Atlanta, Georgia 30309 (US).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: 5-BENZYLIDENE-4-OXAZOLIDINONES

(57) Abstract: Provided herein are compounds that can exhibit activity as biofilm modulating agents (e.g., activity as biofilm inhibitors and/or activity as biofilm dispersal agents). The compounds can exhibit potent activity against Gram positive biofilms. The compounds can also exhibit activity against Gram negative biofilms. In some cases, the compounds can exhibit both biofilm modulation properties and antimicrobial activity. Compositions comprising these compounds, as well as methods of using thereof, are also described. For example, the compounds described herein can be used in human and animal health (e.g., for the treatment of infection), agriculture, marine coatings, and other coating applications related to prevention of biofilm (e.g., dental, medical, etc.).



5-Benzylidene-4-Oxazolidinones

CROSS REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of U.S. Provisional Application No. 62/378,174, filed August 22, 2016, which is incorporated herein by reference in its entirety.

STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT

This invention was made with Government Support under Grant No. GM110154 awarded by the National Institutes of Health. The Government has certain rights in the invention.

BACKGROUND

Biofilms are bacterial communities encased in a hydrated extracellular matrix, which can include proteins, polysaccharides, and/or nucleic acids. The development of biofilms on biological and inanimate surfaces presents significant medical problems. Bacteria in the biofilm mode of growth are highly resistant to treatment with antibiotics and to clearance by a host's immune system. Therefore, once these bacterial communities form, they are extremely difficult to eradicate with conventional treatments. Hence, biofilms can lead to chronic systemic infections. For example, bacterial biofilms have been found in human patients associated with a variety of diseases, including, urinary tract infections, middle ear infections, dental plaque, gingivitis, endocarditis, and the respiratory tract of cystic fibrosis patients. Pathogenic bacteria may form biofilms on a variety of medical implants as well, such as indwelling catheters, artificial heart valves, and pacemakers.

The most clinically relevant characteristic of biofilm bacteria is that they are up to 1000-fold more resistant to antibiotics and biocides than are planktonic bacteria. In addition, biofilm bacteria have also demonstrated resistance to phagocytosis by sentinel leukocytes of the immune system. Accordingly, biofilm bacteria can survive conventional antibiotic treatments, evade a host's immune system, and provide a reservoir of infectious bacteria that can cause recurrent chronic infections.


Biofilm-related infections are currently treated with antibiotics or antibiotic combinations that are optimized to treat infections caused by planktonic bacteria. These treatments usually resolve the symptoms of infection by killing the planktonic bacteria released from the biofilm. However, these existing treatments are generally ineffective against the underlying biofilms associated with the infection.

Accordingly, there is a critical need for compounds and compositions that can control biofilms, as well as improved methods for controlling biofilms.

SUMMARY

Provided herein are compounds that can exhibit activity as biofilm modulating agents (e.g., activity as biofilm inhibitors and/or activity as biofilm dispersal agents). The compounds can exhibit potent activity against Gram positive biofilms. The compounds can also exhibit activity against Gram negative biofilms. In some cases, the compounds can exhibit both biofilm modulation properties and antimicrobial activity.


For example, provided herein are compounds defined by Formula I



Formula I

or a pharmaceutically acceptable salt or prodrug thereof, wherein X is chosen from O and S; R¹, R², R³, R⁴, and R⁵ are each independently chosen from hydrogen, halogen, hydroxyl, -CN, -NO₂, amino, alkylamino, dialkylamino, alkyl, haloalkyl, alkylthio, haloalkylthio, alkoxy, haloalkoxy, alkenyl, haloalkenyl, alkynyl, haloalkynyl, alkylsulfinyl, haloalkylsulfinyl, alkylsulfonyl, haloalkylsulfonyl, alkylcarbonyl, haloalkylcarbonyl, alkoxycarbonyl, haloalkoxycarbonyl, alkylaminocarbonyl, heteroalkylaminocarbonyl, dialkylaminocarbonyl, and heterodialkylaminocarbonyl; R⁶ and R⁷ are each independently chosen from hydrogen, hydroxy, halogen, -CN, -NO₂, amino, alkylamino, dialkylamino, alkyl, haloalkyl, alkylthio, haloalkylthio, alkoxy, haloalkoxy, alkenyl, haloalkenyl, alkynyl, haloalkynyl, alkylsulfinyl, haloalkylsulfinyl, alkylsulfonyl, haloalkylsulfonyl, alkylcarbonyl, haloalkylcarbonyl, alkoxycarbonyl, haloalkoxycarbonyl, alkylaminocarbonyl, heteroalkylaminocarbonyl, dialkylaminocarbonyl, and heterodialkylaminocarbonyl; R⁸ is chosen from alkylamino, dialkylamino, alkyl, haloalkyl, alkylthio, haloalkylthio, alkoxy, haloalkoxy, alkenyl, haloalkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, cycloheteroalkyl, alkylaryl, alkylheteroaryl, alkylcycloalkyl, alkylcycloheteroalkyl, haloalkynyl, alkylsulfinyl, haloalkylsulfinyl, alkylsulfonyl, haloalkylsulfonyl, alkylcarbonyl, haloalkylcarbonyl, alkoxycarbonyl, haloalkoxycarbonyl, alkylaminocarbonyl, heteroalkylaminocarbonyl, dialkylaminocarbonyl, and heterodialkylaminocarbonyl, each optionally substituted with one or more substituents individually chosen from R¹¹; R⁹ is chosen from hydrogen, hydroxy, halogen, -CN, -NO₂, amino, alkylamino, dialkylamino, alkyl, haloalkyl, alkylthio, haloalkylthio, alkoxy, haloalkoxy, alkenyl, haloalkenyl, alkynyl, haloalkynyl, aryl, heteroaryl, cycloalkyl, cycloheteroalkyl, alkylaryl, alkylheteroaryl, alkylcycloalkyl, alkylcycloheteroalkyl, alkylsulfinyl, haloalkylsulfinyl, alkylsulfonyl,

haloalkylsulfonyl, alkylcarbonyl, haloalkylcarbonyl, alkoxy carbonyl, haloalkoxy carbonyl, alkylaminocarbonyl, heteroalkylaminocarbonyl, dialkylaminocarbonyl, and heterodialkylaminocarbonyl, each optionally substituted with one or more substituents individually chosen from R^{11} ; R^{10} is chosen from hydrogen, alkyl, haloalkyl, alkylthio, haloalkylthio, alkenyl, haloalkenyl, alkynyl, haloalkynyl, aryl, heteroaryl, cycloalkyl, cycloheteroalkyl, alkylaryl, alkylheteroaryl, alkylcycloalkyl, and alkylcycloheteroalkyl, each optionally substituted with one or more substituents individually chosen from R^{11} ; and R^{11} is chosen from hydroxy, halogen, -CN, -NO₂, amino, alkylamino, dialkylamino, alkyl, haloalkyl; alkylthio; haloalkylthio; alkoxy, haloalkoxy, alkenyl, haloalkenyl, alkynyl, haloalkynyl, alkylsulfinyl, haloalkylsulfinyl, alkylsulfonyl, haloalkylsulfonyl, alkylcarbonyl, haloalkylcarbonyl, alkoxy carbonyl, haloalkoxy carbonyl, alkylaminocarbonyl, heteroalkylaminocarbonyl, dialkylaminocarbonyl, and heterodialkylaminocarbonyl. In some embodiments, the compound is not one of the following:



In some embodiments, X can be O.

In some embodiments, at least one of R^1 , R^2 , R^3 , R^4 , and R^5 is not hydrogen. In some cases, R^1 , R^2 , R^4 , and R^5 are hydrogen. In certain cases, R^1 , R^2 , R^4 , and R^5 are hydrogen, and R^3 is not hydrogen (e.g., the phenyl ring of the benzylidene moiety is para-substituted).

In some embodiment, R^3 can be an electron withdrawing group. For example, R^3 can be chosen from halogen, -CN, -NO₂, haloalkyl, alkylcarbonyl, haloalkylcarbonyl, alkoxy carbonyl, and haloalkoxy carbonyl. In some embodiments, R^3 can be a haloalkyl group. In certain embodiments, R^3 can be a perfluoroalkyl group (e.g., a -CF₃ group).


In some embodiments, at least one of R^6 and R^7 is not hydrogen. In certain embodiments, both R^6 and R^7 are not hydrogen. In some cases, at least one of R^6 and R^7 can be halogen (e.g., at least one of R^6 and R^7 can be -Cl and/or at least one of R^6 and R^7 can be -F). In some cases, both R^6 and R^7 can be halogen (e.g., both R^6 and R^7 can be -Cl, or both R^6 and R^7 can be -F).

In some examples, R^8 can comprise a substituent having from 5 to 12 carbon atoms. In certain examples, R^8 can be chosen from alkyl, aryl, heteroaryl, alkylaryl, and alkylheteroaryl. In some embodiments, R^8 can comprise a C₁-C₈ alkyl group (e.g., a C₁-C₄ alkyl group, or a C₅-C₈ alkyl group). In other embodiments, R^8 can comprise a C₆-C₁₀ alkylaryl group (e.g., a substituted or unsubstituted benzyl group).

In some embodiments, R^9 can be hydrogen. In other embodiments, R^9 can comprise an alkyl group (e.g., a C₁-C₄ alkyl group) or an aryl group (e.g., a phenyl group).

In some embodiments, R^{10} can be hydrogen. In other embodiments, R^{10} can be an alkyl group, an aryl group, or an alkylaryl group. In certain embodiments, R^{10} can comprise an alkyl group (e.g., a C₁-C₄ alkyl group) or an aryl group (e.g., a phenyl group).

In some cases, the compound can be a compound defined by Formula II




Formula II

or a pharmaceutically acceptable salt or prodrug thereof, wherein R^3 comprises an electron withdrawing group; R^6 and R^7 are each independently chosen from hydrogen and halogen, with the proviso that at least one of R^6 and R^7 is halogen; R^8 is chosen from alkyl, haloalkyl, alkoxy, haloalkoxy, alkenyl, haloalkenyl, alkynyl, haloalkynyl, aryl, heteroaryl, cycloalkyl, cycloheteroalkyl, alkylaryl, alkylheteroaryl, alkylcycloalkyl, alkylcycloheteroalkyl, each optionally substituted with one or more substituents individually chosen from R^{11} ; and R^{11} is chosen from hydroxy, halogen, -CN, -NO₂, amino, alkylamino, dialkylamino, alkyl, haloalkyl, alkylthio, haloalkylthio, alkoxy, haloalkoxy, alkenyl, haloalkenyl, alkynyl, haloalkynyl, alkylsulfinyl, haloalkylsulfinyl, alkylsulfonyl, haloalkylsulfonyl, alkylcarbonyl,

haloalkylcarbonyl, alkoxycarbonyl, haloalkoxycarbonyl, alkylaminocarbonyl, heteroalkylaminocarbonyl, dialkylaminocarbonyl, and heterodialkylaminocarbonyl. In some embodiments, the compound is not one of the following:

5



10 In some embodiments, R^3 can be chosen from halogen, -CN, -NO₂, haloalkyl, alkylcarbonyl, haloalkylcarbonyl, alkoxycarbonyl, and haloalkoxycarbonyl. In some embodiments, R^3 can be a haloalkyl group. In certain embodiments, R^3 can be a perfluoroalkyl group (e.g., a -CF₃ group).

Also provided are compositions that can prevent, remove, and/or inhibit biofilms. Biofilm preventing, removing, or inhibiting compositions can comprise a carrier and an effective amount of a compound described herein to prevent, remove, and/or inhibit a biofilm. The composition can be, for example, a dentifrice composition (e.g., a toothpaste, mouthwash, chewing gum, dental floss, or dental cream) that promotes dental hygiene by preventing, reducing, inhibiting or removing a biofilm.

Also provided herein are pharmaceutical compositions that comprise a compound described herein in a pharmaceutically acceptable carrier. In some embodiments, pharmaceutical compositions can further include one or more additional active agents (e.g., one or more antibiotics).

The compounds described herein can also be disposed on or within a substrate to control biofilm formation on the substrate. Accordingly, also provided are medical devices that comprise a medical device substrate and an effective amount of a compound described herein either coating the substrate, or incorporated into the substrate. The effective amount of the compound can be an effective amount to prevent or inhibit growth of a biofilm on the medical device substrate. The medical device substrate can include, for example, a stent, fastener, port, catheter, scaffold, and/or graft.

Also provided herein are methods for controlling biofilm formation on a substrate.

Methods for controlling biofilm formation on a substrate can comprise contacting the substrate with a compound described herein in an amount effective to inhibit biofilm formation. The biofilm can comprise Gram-positive bacteria or Gram-negative bacteria. In some embodiments, the biofilm can comprise Gram-positive bacteria (e.g., a bacteria of a genus *Staphylococcus*, such as *Staphylococcus aureus*).

Also provided herein are methods for treating chronic bacterial infections. Methods for treating a chronic bacterial infection in a subject in need thereof can comprise administering to said subject a compound described herein in an amount effective to inhibit, reduce, or remove a biofilm component of the chronic bacterial infection. The chronic bacterial infection can comprise, for example, a urinary tract infection, gastritis, a respiratory infection, cystitis, pyelonephritis, osteomyelitis, bacteremia, a skin infection, rosacea, acne, a chronic wound infection, infectious kidney stones, bacterial endocarditis, or a sinus infection.

Also provided are methods of treating subjects infected with a bacterium. Methods of treating a subject infected with a bacterium can comprise administering to the subject a therapeutically effective amount of a compound described herein. In some embodiments, the bacterium can comprise a Gram-positive bacterium. For example, the bacterium can include *Staphylococcus aureus* (methicillin sensitive), *Staphylococcus aureus* (methicillin resistant), *Staphylococcus aureus* (vancomycin resistant), *Streptococcus pneumoniae* (penicillin sensitive), *Streptococcus pneumoniae* (penicillin resistant), *Staphylococcus epidermidis* (multiple drug resistant), *Enterococcus faecalis* (vancomycin sensitive), *Enterococcus faecium* (vancomycin resistant), and/or *Haemophilus influenzae*. In some embodiments, the bacterium can comprise a Gram-negative bacterium. For example, the bacterium can include *Salmonella*, *E. Coli*, *Acinetobacter baumannii*, *Pseudomonas aeruginosa* or *Klebsiella pneumoniae*.

DETAILED DESCRIPTION

Definitions

Terms used herein will have their customary meaning in the art unless specified otherwise. The organic moieties mentioned when defining variable positions within the general formulae described herein (e.g., the term “halogen”) are collective terms for the individual substituents encompassed by the organic moiety. The prefix C_n-C_m indicates in each case the possible number of carbon atoms in the group.

As used herein, by a “subject” is meant an individual. Thus, the “subject” can include domesticated animals (e.g., cats, dogs, etc.), livestock (e.g., cattle, horses, pigs, sheep, goats,

etc.), laboratory animals (*e.g.*, mouse, rabbit, rat, guinea pig, etc.), and birds. “Subject” can also include a mammal, such as a primate or a human.

By “reduce” or other forms of the word, such as “reducing” or “reduction,” is meant lowering of an event or characteristic (*e.g.*, biofilm growth). It is understood that this is typically in relation to some standard or expected value, in other words it is relative, but that it is not always necessary for the standard or relative value to be referred to. For example, “reducing the biofilm component of a chronic bacterial infection” can refer to reducing the rate of growth of a biofilm component of the chronic bacterial infection relative to a standard or a control.

By “prevent” or other forms of the word, such as “preventing” or “prevention,” is meant to stop a particular event or characteristic, to stabilize or delay the development or progression of a particular event or characteristic, or to minimize the chances that a particular event or characteristic will occur. Prevent does not require comparison to a control as it is typically more absolute than, for example, reduce. As used herein, something could be reduced but not prevented, but something that is reduced could also be prevented. Likewise, something could be prevented but not reduced, but something that is prevented could also be reduced. It is understood that where reduce or prevent are used, unless specifically indicated otherwise, the use of the other word is also expressly disclosed.

By “treat” or other forms of the word, such as “treated” or “treatment,” is meant to administer a composition or to perform a method in order to reduce, prevent, inhibit, or eliminate a particular characteristic or event (*e.g.*, a biofilm). The term “control” is used synonymously with the terms “treat” and “modulate.”

“Biofilm” or “biofilms” refer to communities of microorganisms that are attached to a substrate. The microorganisms often excrete a protective and adhesive matrix of polymeric compounds. They often have structural heterogeneity, genetic diversity, and complex community interactions. “Biofilm preventing”, “biofilm removing”, “biofilm inhibiting”, “biofilm reducing”, “biofilm resistant”, “biofilm controlling” or “antifouling” refer to prevention of biofilm formation, inhibition of the establishment or growth of a biofilm, or decrease in the amount of organisms that attach and/or grow upon a substrate, up to and including the complete removal of the biofilm.

As used herein, a “substrate” can include any living or nonliving structure. For example, biofilms often grow on synthetic materials submerged in an aqueous solution or exposed to humid air, but they also can form as floating mats on a liquid surface, in which case the microorganisms are adhering to each other or to the adhesive matrix characteristic of a biofilm.

An “effective amount” of a biofilm preventing, removing or inhibiting composition is that amount which is necessary to carry out the composition's function of preventing, removing or inhibiting a biofilm.

The term “alkyl,” as used herein, refers to saturated straight, branched, cyclic, primary, secondary or tertiary hydrocarbons, including those having 1 to 20 atoms. In some embodiments, alkyl groups will include C₁-C₁₂, C₁-C₁₀, C₁-C₈, C₁-C₆, C₁-C₅, C₁-C₄, C₁-C₃, C₁-C₂, or C₁ alkyl groups. Examples of C₁-C₁₀ alkyl groups include, but are not limited to, methyl, ethyl, propyl, 1-methylethyl, butyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl, pentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, 2,2-dimethylpropyl, 1-ethylpropyl, hexyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl, 2,2-dimethylbutyl, 2,3-dimethylbutyl, 3,3-dimethylbutyl, 1-ethylbutyl, 2-ethylbutyl, 1,1,2-trimethylpropyl, 1,2,2-trimethylpropyl, 1-ethyl-1-methylpropyl, 1-ethyl-2-methylpropyl, heptyl, octyl, 2-ethylhexyl, nonyl and decyl groups, as well as their isomers. Examples of C₁-C₄-alkyl groups include, for example, methyl, ethyl, propyl, 1-methylethyl, butyl, 1-methylpropyl, 2-methylpropyl and 1,1-dimethylethyl groups.

Cyclic alkyl groups or “cycloalkyl” groups, which are encompassed alkyl, include cycloalkyl groups having from 3 to 10 carbon atoms. Cycloalkyl groups can include a single ring, or multiple condensed rings. In some embodiments, cycloalkyl groups include C₃-C₄, C₄-C₇, C₅-C₇, C₄-C₆, or C₅-C₆ cyclic alkyl groups. Non-limiting examples of cycloalkyl groups include adamantyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl and the like.

Alkyl groups can be unsubstituted or substituted with one or more moieties selected from the group consisting of alkyl, halo, haloalkyl, hydroxyl, carboxyl, acyl, acyloxy, amino, alkyl- or dialkylamino, amido, arylamino, alkoxy, aryloxy, nitro, cyano, azido, thiol, imino, sulfonic acid, sulfate, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, ester, phosphonyl, phosphinyl, phosphoryl, phosphine, thioester, thioether, acid halide, anhydride, oxime, hydrazine, carbamate, phosphoric acid, phosphate, phosphonate, or any other viable functional group that does not inhibit the biological activity of the compounds of the invention, either unprotected, or protected as necessary, as known to those skilled in the art, for example, as described in Greene, et al., *Protective Groups in Organic Synthesis*, John Wiley and Sons, Third Edition, 1999, hereby incorporated by reference.

Terms including the term “alkyl,” such as “alkylcycloalkyl,” “cycloalkylalkyl,” “alkylamino,” or “dialkylamino,” will be understood to comprise an alkyl group as defined

above linked to another functional group, where the group is linked to the compound through the last group listed, as understood by those of skill in the art.

The term “alkenyl,” as used herein, refers to both straight and branched carbon chains which have at least one carbon-carbon double bond. In some embodiments, alkenyl groups can include C₂-C₂₀ alkenyl groups. In other embodiments, alkenyl can include C₂-C₁₂, C₂-C₁₀, C₂-C₈, C₂-C₆ or C₂-C₄ alkenyl groups. In one embodiment of alkenyl, the number of double bonds is 1-3, in another embodiment of alkenyl, the number of double bonds is one or two. Other ranges of carbon-carbon double bonds and carbon numbers are also contemplated depending on the location of the alkenyl moiety on the molecule. “C₂-C₁₀-alkenyl” groups may include more than one double bond in the chain. The one or more unsaturations within the alkenyl group may be located at any position(s) within the carbon chain as valence permits. In some embodiments, when the alkenyl group is covalently bound to one or more additional moieties, the carbon atom(s) in the alkenyl group that are covalently bound to the one or more additional moieties are not part of a carbon-carbon double bond within the alkenyl group. Examples of alkenyl groups include, but are not limited to, ethenyl, 1-propenyl, 2-propenyl, 1-methyl-ethenyl, 1-butenyl, 2-butenyl, 3-butenyl, 1-methyl-1-propenyl, 2-methyl-1-propenyl, 1-methyl-2-propenyl, 2-methyl-2-propenyl; 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 1-methyl-1-butenyl, 2-methyl-1-butenyl, 3-methyl-1-butenyl, 1-methyl-2-butenyl, 2-methyl-2-butenyl, 3-methyl-2-butenyl, 1-methyl-3-butenyl, 2-methyl-3-butenyl, 3-methyl-3-butenyl, 1,1-dimethyl-2-propenyl, 1,2-dimethyl-1-propenyl, 1,2-dimethyl-2-propenyl, 1-ethyl-1-propenyl, 1-ethyl-2-propenyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl, 1-methyl-1-pentenyl, 2-methyl-1-pentenyl, 3-methyl-1-pentenyl, 4-methyl-1-pentenyl, 1-methyl-2-pentenyl, 2-methyl-2-pentenyl, 3-methyl-2-pentenyl, 4-methyl-2-pentenyl, 1-methyl-3-pentenyl, 2-methyl-3-pentenyl, 3-methyl-3-pentenyl, 4-methyl-3-pentenyl, 1-methyl-4-pentenyl, 2-methyl-4-pentenyl, 3-methyl-4-pentenyl, 4-methyl-4-pentenyl, 1,1-dimethyl-2-butenyl, 1,1-dimethyl-3-butenyl, 1,2-dimethyl-1-butenyl, 1,2-dimethyl-2-butenyl, 1,2-dimethyl-3-butenyl, 1,3-dimethyl-1-butenyl, 1,3-dimethyl-2-butenyl, 1,3-dimethyl-3-butenyl, 2,2-dimethyl-3-butenyl, 2,3-dimethyl-1-butenyl, 2,3-dimethyl-2-butenyl, 2,3-dimethyl-3-butenyl, 3,3-dimethyl-1-butenyl, 3,3-dimethyl-2-butenyl, 1-ethyl-1-butenyl, 1-ethyl-2-butenyl, 1-ethyl-3-butenyl, 2-ethyl-1-butenyl, 2-ethyl-2-butenyl, 2-ethyl-3-butenyl, 1,1,2-trimethyl-2-propenyl, 1-ethyl-1-methyl-2-propenyl, 1-ethyl-2-methyl-1-propenyl and 1-ethyl-2-methyl-2-propenyl groups.

The term “alkynyl,” as used herein, refers to both straight and branched carbon chains which have at least one carbon-carbon triple bond. In one embodiment of alkynyl, the number of triple bonds is 1-3; in another embodiment of alkynyl, the number of triple bonds is one or two.

In some embodiments, alkynyl groups include from C₂-C₂₀ alkynyl groups. In other embodiments, alkynyl groups may include C₂-C₁₂, C₂-C₁₀, C₂-C₈, C₂-C₆ or C₂-C₄ alkynyl groups. Other ranges of carbon-carbon triple bonds and carbon numbers are also contemplated depending on the location of the alkenyl moiety on the molecule. For example, the term "C₂-C₁₀-alkynyl" as used herein refers to a straight-chain or branched unsaturated hydrocarbon group having 2 to 10 carbon atoms and containing at least one triple bond, such as ethynyl, prop-1-yn-1-yl, prop-2-yn-1-yl, n-but-1-yn-1-yl, n-but-1-yn-3-yl, n-but-1-yn-4-yl, n-but-2-yn-1-yl, n-pent-1-yn-1-yl, n-pent-1-yn-3-yl, n-pent-1-yn-4-yl, n-pent-1-yn-5-yl, n-pent-2-yn-1-yl, n-pent-2-yn-4-yl, n-pent-2-yn-5-yl, 3-methylbut-1-yn-3-yl, 3-methylbut-1-yn-4-yl, n-hex-1-yn-1-yl, n-hex-1-yn-3-yl, n-hex-1-yn-4-yl, n-hex-1-yn-5-yl, n-hex-1-yn-6-yl, n-hex-2-yn-1-yl, n-hex-2-yn-4-yl, n-hex-2-yn-5-yl, n-hex-2-yn-6-yl, n-hex-3-yn-1-yl, n-hex-3-yn-2-yl, 3-methylpent-1-yn-1-yl, 3-methylpent-1-yn-3-yl, 3-methylpent-1-yn-4-yl, 3-methylpent-1-yn-5-yl, 4-methylpent-1-yn-1-yl, 4-methylpent-2-yn-4-yl, and 4-methylpent-2-yn-5-yl groups.

The term "haloalkyl," as used herein refers to an alkyl group, as defined above, which is substituted by one or more halogen atoms. In some instances, the haloalkyl group can be an alkyl group substituted by one or more fluorine atoms. In certain instances, the haloalkyl group can be a perfluorinated alkyl group. For example C₁-C₄-haloalkyl includes, but is not limited to, chloromethyl, bromomethyl, dichloromethyl, trichloromethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chlorofluoromethyl, dichlorofluoromethyl, chlorodifluoromethyl, 1-chloroethyl, 1-bromoethyl, 1-fluoroethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 2-chloro-2-fluoroethyl, 2-chloro-2,2-difluoroethyl, 2,2-dichloro-2-fluoroethyl, 2,2,2-trichloroethyl, and pentafluoroethyl.

The term "haloalkenyl," as used herein, refers to an alkenyl group, as defined above, which is substituted by one or more halogen atoms.

The term "haloalkynyl," as used herein, refers to an alkynyl group, as defined above, which is substituted by one or more halogen atoms.

The term "alkoxy," as used herein, refers to alkyl-O-, wherein alkyl refers to an alkyl group, as defined above. Similarly, the terms "alkenyloxy," "alkynyloxy," "haloalkoxy," "haloalkenyloxy," "haloalkynyloxy," "cycloalkoxy," "cycloalkenyloxy," "halocycloalkoxy," and "halocycloalkenyloxy" refer to the groups alkenyl-O-, alkynyl-O-, haloalkyl-O-, haloalkenyl-O-, haloalkynyl-O-, cycloalkyl-O-, cycloalkenyl-O-, halocycloalkyl-O-, and halocycloalkenyl-O-, respectively, wherein alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, cycloalkyl, cycloalkenyl, halocycloalkyl, and halocycloalkenyl are as defined above. Examples of C₁-C₆-alkoxy include, but are not limited to, methoxy, ethoxy, C₂H₅-CH₂O-, (CH₃)₂CHO-, n-butoxy,

C₂H₅-CH(CH₃)O-, (CH₃)₂CH-CH₂O-, (CH₃)₃CO-, n-pentoxy, 1-methylbutoxy, 2-methylbutoxy, 3-methylbutoxy, 1,1-dimethylpropoxy, 1,2-dimethylpropoxy, 2,2-dimethyl-propoxy, 1-ethylpropoxy, n-hexoxy, 1-methylpentoxy, 2-methylpentoxy, 3-methylpentoxy, 4-methylpentoxy, 1,1-dimethylbutoxy, 1,2-dimethylbutoxy, 1,3-dimethylbutoxy, 2,2-dimethylbutoxy, 2,3-dimethylbutoxy, 3,3-dimethylbutoxy, 1-ethylbutoxy, 2-ethylbutoxy, 1,1,2-trimethylpropoxy, 1,2,2-trimethylpropoxy, 1-ethyl-1-methylpropoxy, and 1-ethyl-2-methylpropoxy.

The term “alkylthio,” as used herein, refers to alkyl-S-, wherein alkyl refers to an alkyl group, as defined above. Similarly, the terms “haloalkylthio,” “cycloalkylthio,” and the like, refer to haloalkyl-S- and cycloalkyl-S- where haloalkyl and cycloalkyl are as defined above.

The term “alkylsulfinyl,” as used herein, refers to alkyl-S(O)-, wherein alkyl refers to an alkyl group, as defined above. Similarly, the term “haloalkylsulfinyl” refers to haloalkyl-S(O)- where haloalkyl is as defined above.

The term “alkylsulfonyl,” as used herein, refers to alkyl-S(O)₂-, wherein alkyl is as defined above. Similarly, the term “haloalkylsulfonyl” refers to haloalkyl-S(O)₂- where haloalkyl is as defined above.

The terms “alkylamino” and “dialkylamino,” as used herein, refer to alkyl-NH- and (alkyl)₂N- groups, where alkyl is as defined above. Similarly, the terms “haloalkylamino” and “halodialkylamino” refer to haloalkyl-NH- and (haloalkyl)₂-NH-, where haloalkyl is as defined above.

The terms “alkylcarbonyl,” “alkoxycarbonyl,” “alkylaminocarbonyl,” and “dialkylaminocarbonyl,” as used herein, refer to alkyl-C(O)-, alkoxy-C(O)-, alkylamino-C(O)- and dialkylamino-C(O)- respectively, where alkyl, alkoxy, alkylamino, and dialkylamino are as defined above. Similarly, the terms “haloalkylcarbonyl,” “haloalkoxycarbonyl,” “haloalkylaminocarbonyl,” and “dihaloalkylaminocarbonyl,” as used herein, refer to the groups haloalkyl-C(O)-, haloalkoxy-C(O)-, haloalkylamino-C(O)-, and dihaloalkylamino-C(O)-, where haloalkyl, haloalkoxy, haloalkylamino, and dihaloalkylamino are as defined above.

The term “aryl,” as used herein, refers to a monovalent aromatic carbocyclic group of from 6 to 14 carbon atoms. Aryl groups can include a single ring or multiple condensed rings. In some embodiments, aryl groups include C₆-C₁₀ aryl groups. Aryl groups include, but are not limited to, phenyl, biphenyl, naphthyl, tetrahydronaphthyl, phenylcyclopropyl and indanyl. Aryl groups may be unsubstituted or substituted by one or more moieties selected from halogen, cyano, nitro, hydroxy, mercapto, amino, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, haloalkyl, haloalkenyl, haloalkynyl, halocycloalkyl, halocycloalkenyl, alkoxy, alkenyloxy,

alkynyloxy, haloalkoxy, haloalkenyloxy, haloalkynyloxy, cycloalkoxy, cycloalkenyloxy, halocycloalkoxy, halocycloalkenyloxy, alkylthio, haloalkylthio, cycloalkylthio, halocycloalkylthio, alkylsulfinyl, alkenylsulfinyl, alkynyl-sulfinyl, haloalkylsulfinyl, haloalkenylsulfinyl, haloalkynylsulfinyl, alkylsulfonyl, alkenylsulfonyl, alkynylsulfonyl, haloalkyl-sulfonyl, haloalkenylsulfonyl, haloalkynylsulfonyl, alkylamino, alkenylamino, alkynylamino, di(alkyl)amino, di(alkenyl)-amino, di(alkynyl)amino, or trialkylsilyl.

The term “alkylaryl,” as used herein, refers to an aryl group that is bonded to a parent compound through a diradical alkylene bridge, $(-CH_2-)_n$, where n is 1-12 and where “aryl” is as defined above.

The term “alkylcycloalkyl,” as used herein, refers to a cycloalkyl group that is bonded to a parent compound through a diradical alkylene bridge, $(-CH_2-)_n$, where n is 1-12 and where “cycloalkyl” is as defined above. The term “cycloalkylalkyl,” as used herein, refers to a cycloalkyl group, as defined above, which is substituted by an alkyl group, as defined above.

The term “heteroalkyl,” as used herein, refers to an alkyl group, as described above, which includes one or more heteroatoms (e.g., from one to four heteroatoms) within the carbon backbone. In some cases, the heteroatom(s) incorporated into the carbon backbone are oxygen, nitrogen, sulfur, or combinations thereof. The terms “heteroalkenyl” and “heteroalkynyl,” as used herein, likewise refer to alkenyl and alkynyl groups respectively which include one or more heteroatoms (e.g., from one to four heteroatoms, such as oxygen, nitrogen, sulfur, or combinations thereof) within their carbon backbone.

The term “heteroaryl,” as used herein, refers to a monovalent aromatic group of from 1 to 15 carbon atoms (e.g., from 1 to 10 carbon atoms, from 2 to 8 carbon atoms, from 3 to 6 carbon atoms, or from 4 to 6 carbon atoms) having one or more heteroatoms within the ring. The heteroaryl group can include from 1 to 4 heteroatoms, from 1 to 3 heteroatoms, or from 1 to 2 heteroatoms. In some cases, the heteroatom(s) incorporated into the ring are oxygen, nitrogen, sulfur, or combinations thereof. When present, the nitrogen and sulfur heteroatoms may optionally be oxidized. Heteroaryl groups can have a single ring (e.g., pyridyl or furyl) or multiple condensed rings provided that the point of attachment is through a heteroaryl ring atom. Preferred heteroaryls include pyridyl, piridaziny, pyrimidinyl, pyrazinyl, triazinyl, pyrrolyl, indolyl, quinoliny, isoquinoliny, quinazoliny, quinoxaliny, furanyl, thiophenyl, furyl, pyrrolyl, imidazolyl, oxazolyl, isoxazolyl, isothiazolyl, pyrazolyl benzofuranyl, and benzothiophenyl. Heteroaryl rings may be unsubstituted or substituted by one or more moieties as described for aryl above.

The term “alkylheteroaryl,” as used herein, refers to a heteroaryl group that is bonded to a parent compound through a diradical alkylene bridge, $(-\text{CH}_2-)_n$, where n is 1-12 and where “heteroaryl” is as defined above.

The terms “cycloheteroalkyl,” “heterocyclyl,” “heterocyclic,” and “heterocyclo” are used herein interchangeably, and refer to fully saturated or unsaturated, cyclic groups, for example, 3 to 7 membered monocyclic or 4 to 7 membered monocyclic; 7 to 11 membered bicyclic, or 10 to 15 membered tricyclic ring systems, having one or more heteroatoms within the ring. The heterocyclyl group can include from 1 to 4 heteroatoms, from 1 to 3 heteroatoms, or from 1 to 2 heteroatoms. In some cases, the heteroatom(s) incorporated into the ring are oxygen, nitrogen, sulfur, or combinations thereof. When present, the nitrogen and sulfur heteroatoms may optionally be oxidized, and the nitrogen heteroatoms may optionally be quaternized. The heterocyclyl group may be attached at any heteroatom or carbon atom of the ring or ring system and may be unsubstituted or substituted by one or more moieties as described for aryl groups above.

Exemplary monocyclic heterocyclic groups include, but are not limited to, pyrrolidinyl, pyrrolyl, pyrazolyl, oxetanyl, pyrazolinyl, imidazolyl, imidazolinyl, imidazolidinyl, oxazolyl, oxazolidinyl, isoxazolinyl, isoxazolyl, thiazolyl, thiadiazolyl, thiazolidinyl, isothiazolyl, isothiazolidinyl, furyl, tetrahydrofuryl, thienyl, oxadiazolyl, piperidinyl, piperazinyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolodinyl, 2-oxoazepinyl, azepinyl, 4-piperidonyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, tetrahydropyranyl, morpholinyl, thiamorpholinyl, thiamorpholinyl sulfoxide, thiamorpholinyl sulfone, 1,3-dioxolane and tetrahydro-1,1-dioxothienyl, triazolyl, triazinyl, and the like.

Exemplary bicyclic heterocyclic groups include, but are not limited to, indolyl, benzothiazolyl, benzoxazolyl, benzodioxolyl, benzothienyl, quinuclidinyl, quinolinyl, tetrahydroisoquinolinyl, isoquinolinyl, benzimidazolyl, benzopyranyl, indolizinyl, benzofuryl, chromonyl, coumarinyl, benzopyranyl, cinnolinyl, quinoxalinyl, indazolyl, pyrrolopyridyl, furopyridinyl (such as furo[2,3-c]pyridinyl, furo[3,2-b]pyridinyl or furo[2,3-b]pyridinyl), dihydroisoindolyl, dihydroquinazolinyl (such as 3,4-dihydro-4-oxo-quinazolinyl), tetrahydroquinolinyl and the like.

Exemplary tricyclic heterocyclic groups include carbazolyl, benzidolyl, phenanthrolinyl, acridinyl, phenanthridinyl, xanthenyl, and the like.

The term “alkylheterocyclyl” and “alkylcycloheteroalkyl” are used herein interchangeably, and refer to a heterocyclyl group that is bonded to a parent compound through a diradical alkylene bridge, $(-\text{CH}_2-)_n$, where n is 1-12 and where “heterocyclyl” is as defined

above. The term “heterocyclylalkyl,” as used herein, refers to a heterocyclyl group, as defined above, which is substituted by an alkyl group, as defined above.

The term “halogen,” as used herein, refers to the atoms fluorine, chlorine, bromine and iodine. The prefix halo- (e.g., as illustrated by the term haloalkyl) refers to all degrees of halogen substitution, from a single substitution to a perhalo substitution (e.g., as illustrated with methyl as chloromethyl (-CH₂Cl), dichloromethyl (-CHCl₂), trichloromethyl (-CCl₃)).

As used herein, the term “substituted” is contemplated to include all permissible substituents of organic compounds. In a broad aspect, the permissible substituents include acyclic and cyclic, branched and unbranched, carbocyclic and heterocyclic, and aromatic and nonaromatic substituents of organic compounds. Illustrative substituents include, for example, those described below. The permissible substituents can be one or more and the same or different for appropriate organic compounds. For purposes of this disclosure, the heteroatoms, such as nitrogen, can have hydrogen substituents and/or any permissible substituents of organic compounds described herein which satisfy the valences of the heteroatoms. This disclosure is not intended to be limited in any manner by the permissible substituents of organic compounds. Also, the terms “substitution” or “substituted with” include the implicit proviso that such substitution is in accordance with permitted valence of the substituted atom and the substituent, and that the substitution results in a stable compound, *e.g.*, a compound that does not spontaneously undergo transformation such as by rearrangement, cyclization, elimination, etc.

Stereoisomers and polymorphic forms

Unless stated to the contrary, a formula with chemical bonds shown only as solid lines and not as wedges or dashed lines contemplates each possible isomer, *e.g.*, each enantiomer, diastereomer, and meso compound, and a mixture of isomers, such as a racemic or scalemic mixture.

The compounds described herein can exist and be isolated as optically active and racemic forms. The compounds can have one or more chiral centers, including at a sulfur atom, and thus exist as one or more stereoisomers. Where compounds include *n* chiral centers, the compounds can comprise up to 2^{*n*} optical isomers. Such stereoisomer-containing compounds can exist as a single enantiomer, a mixture of enantiomers, a mixture of diastereomers, or a racemic mixture. The optically active forms can be prepared by, for example, resolution of the racemic forms by selective crystallization techniques, by synthesis from optically active precursors, by chiral synthesis, by chromatographic separation using a chiral stationary phase or by enzymatic resolution.

The compounds can also be present in different solid forms, including different crystalline forms (i.e., different crystalline polymorphs of the compounds) or as an amorphous solid. In addition, the compounds can exist as hydrates or solvates, in which a certain stoichiometric amount of water or a solvent is associated with the molecule in the crystalline form. In some embodiments, the compositions described herein can include up to 15% (w/w), up to 20% (w/w), or up to 30% (w/w) of a particular solid form of the compounds described herein, based on the total weight of the composition.

Pharmaceutically acceptable salts

The compounds described herein can also be provided as pharmaceutically acceptable salts (e.g., acid or base salts) where applicable, of the compounds described herein.

Pharmaceutically acceptable salts are known in the art. *See*, for example, Remington's Pharmaceutical Sciences, 20th ed., Lippincott Williams & Wilkins, Baltimore, MD, 2000, p. 704.

The term "acid salt" contemplates salts of the compounds with all pharmaceutically acceptable inorganic or organic acids. Inorganic acids include mineral acids such as hydrohalic acids such as hydrobromic acid and hydrochloric acid, sulfuric acid, phosphoric acids and nitric acid. Organic acids include all pharmaceutically acceptable aliphatic, alicyclic and aromatic carboxylic acids, dicarboxylic acids, tricarboxylic acids and fatty acids. In one embodiment of the acids, the acids are straight chain or branched, saturated or unsaturated C₁-C₂₀ aliphatic carboxylic acids, which are optionally substituted by halogen or by hydroxyl groups, or C₆-C₁₂ aromatic carboxylic acids. Examples of such acids are carbonic acid, formic acid, acetic acid, propionic acid, isopropionic acid, valeric acid, α -hydroxy acids such as glycolic acid and lactic acid, chloroacetic acid, benzoic acid, methane sulfonic acid, and salicylic acid. Examples of dicarboxylic acids include oxalic acid, malic acid, succinic acid, tartaric acid, fumaric acid, and maleic acid. An example of a tricarboxylic acid is citric acid. Fatty acids include all pharmaceutically acceptable saturated or unsaturated aliphatic or aromatic carboxylic acids having 4 to 24 carbon atoms. Examples include butyric acid, isobutyric acid, sec-butyric acid, lauric acid, palmitic acid, stearic acid, oleic acid, linoleic acid, linolenic acid, and phenylstearic acid. Other acids include gluconic acid, glycoheptonic acid and lactobionic acid.

The term "base salt" contemplates salts of the compounds with all pharmaceutically acceptable inorganic or organic bases, including hydroxides, carbonates or bicarbonates of alkali metal or alkaline earth metals. Salts formed with such bases include, for example, the alkali metal and alkaline earth metal salts, including, but not limited to, as the lithium, sodium, potassium, magnesium or calcium salts. Salts formed with organic bases include the common

hydrocarbon and heterocyclic amine salts, which include, for example, ammonium salts (NH_4^+), alkylammonium salts, and dialkylammonium salts, as well as salts of cyclic amines such as the morpholine and piperidine salts.


Prodrugs

The compounds described herein can also be provided as pharmaceutically acceptable prodrugs. Prodrugs are compounds that, when metabolized *in vivo*, undergo conversion to compounds described herein having the desired pharmacological activity. Prodrugs can be prepared by replacing appropriate functionalities present in the compounds described herein with "pro-moieties" as described, for example, in H. Bundgaard, *Design of Prodrugs* (1985). Examples of prodrugs include ester, ether or amide derivatives of the compounds described herein, as well as their pharmaceutically acceptable salts. For further discussions of prodrugs, *see*, for example, T. Higuchi and V. Stella "Pro-drugs as Novel Delivery Systems," ACS Symposium Series 14 (1975) and E. B. Roche ed., *Bioreversible Carriers in Drug Design* (1987).

Compounds

Provided herein are compounds that can exhibit activity as biofilm modulating agents (e.g., activity as biofilm inhibitors and/or activity as biofilm dispersal agents). The compounds can exhibit potent activity against Gram positive biofilms. The compounds can also exhibit activity against Gram negative biofilms. In some cases, the compounds can exhibit both biofilm modulation properties and antimicrobial activity.


For example, provided herein are compounds defined by Formula I




Formula I

or a pharmaceutically acceptable salt or prodrug thereof, wherein X is chosen from O and S; R^1 , R^2 , R^3 , R^4 , and R^5 are each independently chosen from hydrogen, halogen, hydroxyl, -CN, -NO₂, amino, alkylamino, dialkylamino, alkyl, haloalkyl, alkylthio, haloalkylthio, alkoxy, haloalkoxy, alkenyl, haloalkenyl, alkynyl, haloalkynyl, alkylsulfinyl, haloalkylsulfinyl, alkylsulfonyl, haloalkylsulfonyl, alkylcarbonyl, haloalkylcarbonyl, alkoxycarbonyl, haloalkoxycarbonyl, alkylaminocarbonyl, heteroalkylaminocarbonyl, dialkylaminocarbonyl, and heterodialkylaminocarbonyl; R^6 and R^7 are each independently chosen from hydrogen, hydroxy, halogen, -CN, -NO₂, amino, alkylamino, dialkylamino, alkyl, haloalkyl, alkylthio, haloalkylthio, alkoxy, haloalkoxy, alkenyl, haloalkenyl, alkynyl, haloalkynyl, alkylsulfinyl, haloalkylsulfinyl,

alkylsulfonyl, haloalkylsulfonyl, alkylcarbonyl, haloalkylcarbonyl, alkoxycarbonyl, haloalkoxycarbonyl, alkylaminocarbonyl, heteroalkylaminocarbonyl, dialkylaminocarbonyl, and heterodialkylaminocarbonyl; R^8 is chosen from alkylamino, dialkylamino, alkyl, haloalkyl, alkylthio, haloalkylthio, alkoxy, haloalkoxy, alkenyl, haloalkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, cycloheteroalkyl, alkylaryl, alkylheteroaryl, alkylcycloalkyl, alkylcycloheteroalkyl, haloalkynyl, alkylsulfinyl, haloalkylsulfinyl, alkylsulfonyl, haloalkylsulfonyl, alkylcarbonyl, haloalkylcarbonyl, alkoxycarbonyl, haloalkoxycarbonyl, alkylaminocarbonyl, heteroalkylaminocarbonyl, dialkylaminocarbonyl, and heterodialkylaminocarbonyl, each optionally substituted with one or more substituents individually chosen from R^{11} ; R^9 is chosen from hydrogen, hydroxy, halogen, -CN, -NO₂, amino, alkylamino, dialkylamino, alkyl, haloalkyl, alkylthio, haloalkylthio, alkoxy, haloalkoxy, alkenyl, haloalkenyl, alkynyl, haloalkynyl, aryl, heteroaryl, cycloalkyl, cycloheteroalkyl, alkylaryl, alkylheteroaryl, alkylcycloalkyl, alkylcycloheteroalkyl, alkylsulfinyl, haloalkylsulfinyl, alkylsulfonyl, haloalkylsulfonyl, alkylcarbonyl, haloalkylcarbonyl, alkoxycarbonyl, haloalkoxycarbonyl, alkylaminocarbonyl, heteroalkylaminocarbonyl, dialkylaminocarbonyl, and heterodialkylaminocarbonyl, each optionally substituted with one or more substituents individually chosen from R^{11} ; R^{10} is chosen from hydrogen, alkyl, haloalkyl, alkylthio, haloalkylthio, alkenyl, haloalkenyl, alkynyl, haloalkynyl, aryl, heteroaryl, cycloalkyl, cycloheteroalkyl, alkylaryl, alkylheteroaryl, alkylcycloalkyl, and alkylcycloheteroalkyl, each optionally substituted with one or more substituents individually chosen from R^{11} ; and R^{11} is chosen from hydroxy, halogen, -CN, -NO₂, amino, alkylamino, dialkylamino, alkyl, haloalkyl, alkylthio, haloalkylthio, alkoxy, haloalkoxy, alkenyl, haloalkenyl, alkynyl, haloalkynyl, alkylsulfinyl, haloalkylsulfinyl, alkylsulfonyl, haloalkylsulfonyl, alkylcarbonyl, haloalkylcarbonyl, alkoxycarbonyl, haloalkoxycarbonyl, alkylaminocarbonyl, heteroalkylaminocarbonyl, dialkylaminocarbonyl, and heterodialkylaminocarbonyl. In some embodiments, the compound is not one of the following:





In some embodiments, X can be O.

5 In some embodiments, at least one of R^1 , R^2 , R^3 , R^4 , and R^5 is not hydrogen. In some cases, R^1 , R^2 , R^4 , and R^5 are hydrogen. In certain cases, R^1 , R^2 , R^4 , and R^5 are hydrogen, and R^3 is not hydrogen (e.g., the phenyl ring of the benzylidene moiety is para-substituted).

In some embodiment, R^3 can be an electron withdrawing group. For example, R^3 can be chosen from halogen, -CN, -NO₂, haloalkyl, alkylcarbonyl, haloalkylcarbonyl, alkoxy carbonyl, 10 and haloalkoxy carbonyl. In some embodiments, R^3 can be a haloalkyl group. In certain embodiments, R^3 can be a perfluoroalkyl group (e.g., a -CF₃ group).


In some embodiments, at least one of R^6 and R^7 is not hydrogen. In certain embodiments, both R^6 and R^7 are not hydrogen. In some cases, at least one of R^6 and R^7 can be halogen (e.g., at least one of R^6 and R^7 can be -Cl and/or at least one of R^6 and R^7 can be -F). In 15 some cases, both R^6 and R^7 can be halogen (e.g., both R^6 and R^7 can be -Cl, or both R^6 and R^7 can be -F).

In some examples, R^8 can comprise a substituent having from 5 to 12 carbon atoms. In certain examples, R^8 can be chosen from alkyl, aryl, heteroaryl, alkylaryl, and alkylheteroaryl. In some embodiments, R^8 can comprise a C₁-C₈ alkyl group (e.g., a C₁-C₄ alkyl group, or a C₅- 20 C₈ alkyl group). In other embodiments, R^8 can comprise a C₆-C₁₀ alkylaryl group (e.g., a substituted or unsubstituted benzyl group).

In some embodiments, R^9 can be hydrogen. In other embodiments, R^9 can comprise an alkyl group (e.g., a C₁-C₄ alkyl group) or an aryl group (e.g., a phenyl group).


In some embodiments, R^{10} can be hydrogen. In other embodiments, R^{10} can be an alkyl 25 group, an aryl group, or an alkylaryl group. In certain embodiments, R^{10} can comprise an alkyl group (e.g., a C₁-C₄ alkyl group) or an aryl group (e.g., a phenyl group).

In some cases, the compound can be a compound defined by Formula II




Formula II

or a pharmaceutically acceptable salt or prodrug thereof, wherein R^3 comprises an electron withdrawing group; R^6 and R^7 are each independently chosen from hydrogen and halogen, with the proviso that at least one of R^6 and R^7 is halogen; R^8 is chosen from alkyl, haloalkyl, alkoxy, haloalkoxy, alkenyl, haloalkenyl, alkynyl, haloalkynyl, aryl, heteroaryl, cycloalkyl, cycloheteroalkyl, alkylaryl, alkylheteroaryl, alkylcycloalkyl, alkylcycloheteroalkyl, each optionally substituted with one or more substituents individually chosen from R^{11} ; and R^{11} is chosen from hydroxy, halogen, -CN, -NO₂, amino, alkylamino, dialkylamino, alkyl, haloalkyl, alkylthio; haloalkylthio; alkoxy, haloalkoxy, alkenyl, haloalkenyl, alkynyl, haloalkynyl, alkylsulfinyl, haloalkylsulfinyl, alkylsulfonyl, haloalkylsulfonyl, alkylcarbonyl, haloalkylcarbonyl, alkoxy carbonyl, haloalkoxy carbonyl, alkylaminocarbonyl, heteroalkylaminocarbonyl, dialkylaminocarbonyl, and heterodialkylaminocarbonyl. In some embodiments, the compound is not one of the following:




In some embodiments, R^3 can be chosen from halogen, -CN, -NO₂, haloalkyl, alkylcarbonyl, haloalkylcarbonyl, alkoxy carbonyl, and haloalkoxy carbonyl. In some embodiments, R^3 can be a haloalkyl group. In certain embodiments, R^3 can be a perfluoroalkyl group (e.g., a -CF₃ group).


In some embodiments, the compound can be one of the following:



In some embodiments, the compound can be one of the following:



5 In some embodiments, the compound can be a compound defined by Formula III



Formula III

or a pharmaceutically acceptable salt or prodrug thereof, wherein R^3 comprises an electron withdrawing group; Y is chosen from $-NH_2$, $-NR^{12}H$, $-NR^{12}R^{13}$, or $-^+NR^{12}R^{13}R^{14}$; R^{12} , R^{13} , and R^{14} are individually chosen from alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, alkylthio, haloalkylthio, alkoxy, haloalkoxy, aryl, heteroaryl, cycloalkyl, cycloheteroalkyl, alkylaryl, alkylheteroaryl, alkylcycloalkyl, alkylcycloheteroalkyl, alkylsulfinyl, haloalkylsulfinyl, alkylsulfonyl, haloalkylsulfonyl, alkylcarbonyl, haloalkylcarbonyl, alkoxycarbonyl, haloalkoxycarbonyl, alkylaminocarbonyl, heteroalkylaminocarbonyl, dialkylaminocarbonyl, and heterodialkylaminocarbonyl, each optionally substituted with one or more substituents individually chosen from R^{11} ; R^6 and R^7 are each independently chosen from hydrogen and halogen, with the proviso that at least one of R^6 and R^7 is halogen; R^8 is chosen from alkyl, haloalkyl, alkoxy, haloalkoxy, alkenyl, haloalkenyl, alkynyl, haloalkynyl, aryl, heteroaryl, cycloalkyl, cycloheteroalkyl, alkylaryl, alkylheteroaryl, alkylcycloalkyl, alkylcycloheteroalkyl, each optionally substituted with one or more substituents individually chosen from R^{11} ; and R^{11} is chosen from hydroxy, halogen, $-CN$, $-NO_2$, amino, alkylamino, dialkylamino, alkyl, haloalkyl, alkylthio, haloalkylthio, alkoxy, haloalkoxy, alkenyl, haloalkenyl, alkynyl, haloalkynyl,

alkylsulfinyl, haloalkylsulfinyl, alkylsulfonyl, haloalkylsulfonyl, alkylcarbonyl, haloalkylcarbonyl, alkoxycarbonyl, haloalkoxycarbonyl, alkylaminocarbonyl, heteroalkylaminocarbonyl, dialkylaminocarbonyl, and heterodialkylaminocarbonyl.


In some cases, R^3 can be chosen from halogen, $-\text{CN}$, $-\text{NO}_2$, haloalkyl, alkylcarbonyl, haloalkylcarbonyl, alkoxycarbonyl, and haloalkoxycarbonyl. In some embodiments, R^3 can be a haloalkyl group. In certain embodiments, R^3 can be a perfluoroalkyl group (e.g., a $-\text{CF}_3$ group).

In some embodiments, both R^6 and R^7 are not hydrogen. In some cases, at least one of R^6 and R^7 can be $-\text{Cl}$ and/or at least one of R^6 and R^7 can be $-\text{F}$. In some cases, both R^6 and R^7 can be $-\text{Cl}$, or both R^6 and R^7 can be $-\text{F}$.

In some examples, R^8 can comprise a substituent having from 5 to 12 carbon atoms. In certain examples, R^8 can be chosen from alkyl, aryl, heteroaryl, alkylaryl, and alkylheteroaryl. In some embodiments, R^8 can comprise a C_1 - C_8 alkyl group (e.g., a C_1 - C_4 alkyl group, or a C_5 - C_8 alkyl group). In some embodiments, R^8 can comprise a linear C_4 alkyl group. In other embodiments, R^8 can comprise a C_6 - C_{10} alkylaryl group (e.g., a substituted or unsubstituted benzyl group).

In some embodiments, R^{12} , R^{13} , and R^{14} , when present, represent alkyl groups (e.g., linear alkyl groups or branched alkyl group). In some embodiments, R^{12} , R^{13} , and R^{14} , when present, can comprise a C_1 - C_4 alkyl group (e.g., a C_2 - C_4 alkyl group). In certain embodiments, R^{12} , R^{13} , and R^{14} , when present, can comprise a C_3 - C_4 alkyl group (e.g., a branched C_3 - C_4 alkyl group, such as an isopropyl group). In other embodiments, R^{12} , R^{13} , and R^{14} , when present, can comprise an aryl group or an alkylaryl group.

In some embodiments, the compound can be a compound defined by Formula IV



Formula IV

or a pharmaceutically acceptable salt or prodrug thereof, wherein R^3 comprises an electron withdrawing group; X is absent or represents a bivalent linking moiety; Y is chosen from $-\text{NH}_2$, $-\text{NR}^{12}\text{H}$, $-\text{NR}^{12}\text{R}^{13}$, or $-\text{NR}^{12}\text{R}^{13}\text{R}^{14}$; R^{12} , R^{13} , and R^{14} are individually chosen from alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, alkylthio, haloalkylthio, alkoxy, haloalkoxy, aryl, heteroaryl, cycloalkyl, cycloheteroalkyl, alkylaryl, alkylheteroaryl, alkylcycloalkyl, alkylcycloheteroalkyl, alkylsulfinyl, haloalkylsulfinyl, alkylsulfonyl, haloalkylsulfonyl, alkylcarbonyl, haloalkylcarbonyl, alkoxycarbonyl, haloalkoxycarbonyl, alkylaminocarbonyl, heteroalkylaminocarbonyl, dialkylaminocarbonyl, and

heterodialkylaminocarbonyl, each optionally substituted with one or more substituents individually chosen from R^{11} ; and R^{11} is chosen from hydroxy, halogen, -CN, -NO₂, amino, alkylamino, dialkylamino, alkyl, haloalkyl; alkylthio; haloalkylthio; alkoxy, haloalkoxy, alkenyl, haloalkenyl, alkynyl, haloalkynyl, alkylsulfinyl, haloalkylsulfinyl, alkylsulfonyl, haloalkylsulfonyl, alkylcarbonyl, haloalkylcarbonyl, alkoxycarbonyl, haloalkoxycarbonyl, alkylaminocarbonyl, heteroalkylaminocarbonyl, dialkylaminocarbonyl, and heterodialkylaminocarbonyl.

In some cases, R^3 can be chosen from halogen, -CN, -NO₂, haloalkyl, alkylcarbonyl, haloalkylcarbonyl, alkoxycarbonyl, and haloalkoxycarbonyl. In some embodiments, R^3 can be a haloalkyl group. In certain embodiments, R^3 can be a perfluoroalkyl group (e.g., a -CF₃ group).

In some embodiments, X is absent. On other embodiments, X is present. When present, the linking group can be any suitable group or moiety which is at minimum bivalent, and connects Y to the carbonyl moiety. The linking group can be composed of any assembly of atoms. In some cases, the total number of atoms in the linking group can be from 3 to 20 atoms (e.g., from 3 to 15 atoms, or from 3 to 10 atoms). In some embodiments, the linking group can be, for example, an alkyl, alkoxy, alkylaryl, alkylheteroaryl, alkylcycloalkyl, alkylheterocycloalkyl, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, dialkylamino, alkylcarbonyl, alkoxycarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, or polyamino group. In certain embodiments, the linking group can be substituted with one or two halogens (e.g., one or two -Cl, or one or two -F) at a position attached to the oxazolidinone ring.

In some embodiments, R^{12} , R^{13} , and R^{14} , when present, represent alkyl groups (e.g., linear alkyl groups or branched alkyl group). In some embodiments, R^{12} , R^{13} , and R^{14} , when present, can comprise a C₁-C₄ alkyl group (e.g., a C₂-C₄ alkyl group). In certain embodiments, R^{12} , R^{13} , and R^{14} , when present, can comprise a C₃-C₄ alkyl group (e.g., a branched C₃-C₄ alkyl group, such as an isopropyl group). In other embodiments, R^{12} , R^{13} , and R^{14} , when present, can comprise an aryl group or an alkylaryl group.

Compositions

Also provided are compositions that include one or more of the compounds described herein. In some embodiments, biofilm preventing, removing or inhibiting compositions are provided, comprising a carrier and an effective amount of a compound described herein.

In some embodiments, the carrier can be a pharmaceutically acceptable carrier. A “pharmaceutically acceptable carrier” as used herein refers to a carrier that, when combined with a compound described herein, facilitates the application or administration of that compound

described herein for its intended purpose (e.g., to prevent or inhibit biofilm formation, or remove an existing biofilm). The compound described herein may be formulated for administration in a pharmaceutically acceptable carrier in accordance with known techniques. See, e.g., Remington, The Science And Practice of Pharmacy (9th Ed. 1995). The pharmaceutically acceptable carrier can, of course, also be acceptable in the sense of being compatible with any other ingredients in the composition.

The carrier may be a solid or a liquid, or both, and is preferably formulated with the a compound described herein as a unit-dose composition, for example, a tablet, which may contain from 0.01 or 0.5% to 95% or 99% by weight of the a compound described herein. One or more a compounds described herein can be included in the compositions, which may be prepared by any of the well-known techniques of pharmacy comprising admixing the components, optionally including one or more accessory ingredients.

In general, compositions may be prepared by uniformly and intimately admixing the a compound described herein with a liquid or finely divided solid carrier, or both, and then, if necessary, shaping the resulting mixture. For example, a tablet may be prepared by compressing or molding a powder or granules containing the a compound described herein, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing, in a suitable machine, the compound in a free-flowing form, such as a powder or granules optionally mixed with a binder, lubricant, inert diluent, and/or surface active/dispersing agent(s). Molded tablets may be made by molding, in a suitable machine, the powdered compound moistened with an inert liquid binder.

Compositions can be formulated to be suitable for oral, rectal, topical, buccal (e.g., sublingual), vaginal, parenteral (e.g., subcutaneous, intramuscular, intradermal, or intravenous), topical (i.e., both skin and mucosal surfaces, including airway surfaces) or transdermal administration, although the most suitable route in any given case will depend on the nature and severity of the condition being treated and on the nature of the particular compound that is being used.

Compositions suitable for oral administration may be presented in discrete units, such as capsules, cachets, lozenges, or tablets, each containing a predetermined amount of the compound; as a powder or granules; as a solution or a suspension in an aqueous or non-aqueous liquid; or as an oil-in-water or water-in-oil emulsion. Such compositions may be prepared by any suitable method of pharmacy, which includes the step of bringing into association the compound and a suitable carrier (which may contain one or more accessory ingredients as noted above).

Compositions suitable for buccal (sub-lingual) administration include lozenges comprising the compound in a flavored base, usually sucrose and acacia or tragacanth; and pastilles comprising the compound in an inert base such as gelatin and glycerin or sucrose and acacia.

5 Compositions suitable for parenteral administration comprise sterile aqueous and non-aqueous injection solutions of the compound, which preparations are preferably isotonic with the blood of the intended recipient. These preparations may contain anti-oxidants, buffers, bacteriostats and solutes that render the composition isotonic with the blood of the intended recipient. Aqueous and non-aqueous sterile suspensions may include suspending agents and
10 thickening agents. The compositions may be presented in unit/dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example, saline or water-for-injection immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described.

15 For example, the composition can be an injectable, stable, sterile composition comprising a compound described herein in a unit dosage form in a sealed container. The composition can be provided in the form of a lyophilizate that can be reconstituted with a suitable pharmaceutically acceptable carrier to form a liquid composition suitable for injection thereof into a subject. The unit dosage form can comprise from about 10 mg to about 10 grams of the compound. When the
20 compound or salt is substantially water-insoluble, a sufficient amount of emulsifying agent that is physiologically acceptable may be employed in sufficient quantity to emulsify the compound or salt in an aqueous carrier. One such useful emulsifying agent is phosphatidyl choline.

Compositions suitable for rectal administration can be presented as unit dose suppositories. These may be prepared by mixing the active compound with one or more
25 conventional solid carriers, for example, cocoa butter, and then shaping the resulting mixture.

Compositions suitable for topical application to the skin can take the form of an ointment, cream, lotion, paste, gel, spray, aerosol, or oil. Carriers that may be used include petroleum jelly, lanoline, polyethylene glycols, alcohols, transdermal enhancers, and combinations of two or more thereof.

30 Compositions suitable for transdermal administration can be presented as discrete patches adapted to remain in intimate contact with the epidermis of the recipient for a prolonged period of time. Compositions suitable for transdermal administration may also be delivered by iontophoresis and typically take the form of an optionally buffered aqueous solution of the active compound.

In some embodiments, the compositions described herein can further include one or more additional active agents, such as a biocide. A “biocide” as used herein refers to a substance with the ability to kill or to inhibit the growth of microorganisms (e.g., bacteria, fungal cells, protozoa, etc.), which is not compound described in the compounds section above. Common biocides include oxidizing and non-oxidizing chemicals.

In some embodiments, the compositions described herein can further include one or more antibiotics. An “antibiotic” as used herein is a type of “biocide.” Common antibiotics include aminoglycosides, carbacephems (e.g., loracarbef), carbapenems, cephalosporins, glycopeptides (e.g., teicoplanin and vancomycin), macrolides, monobactams (e.g., aztreonam) penicillins, polypeptides (e.g., bacitracin, colistin, polymyxin B), quinolones, sulfonamides, tetracyclines, etc. Antibiotics treat infections by either killing or preventing the growth of microorganisms. Many act to inhibit cell wall synthesis or other vital protein synthesis of the microorganisms.

Aminoglycosides are commonly used to treat infections caused by Gram-negative bacteria such as *Escherichia coli* and *Klebsiella*, particularly *Pseudomonas aeruginosa*.

Examples of aminoglycosides include, but are not limited to amikacin, gentamicin, kanamycin, neomycin, netilmicin, streptomycin, tobramycin, and paromomycin.

Carbapenems are broad-spectrum antibiotics, and include, but are not limited to, ertapenem, doripenem, imipenem/cilastatin, and meropenem.

Cephalosporins include, but are not limited to, cefadroxil, cefazolin, cefalotin (cefalothin), cefalexin, cefaclor, cefamandole, cefoxitin, cefprozil, loracarbef, cefuroxime, cefixime, cefdinir, cefditoren, cefoperazone, cefotaxime, cefpodoxime, ceftazidime, ceftibuten, ceftizoxime, ceftriaxone, cefepime, ceftiofime, and ceftibiprole.

Macrolides include, but are not limited to, azithromycin, clarithromycin, dirithromycin, erythromycin, roxithromycin, troleandomycin, telithromycin and spectinomycin.

Penicillins include, but are not limited to, amoxicillin, ampicillin, azlocillin, bacampicillin, carbenicillin, cloxacillin, dicloxacillin, flucloxacillin, mezlocillin, meticillin, nafcillin, oxacillin, penicillin, piperacillin and ticarcillin.

Quinolones include, but are not limited to, ciprofloxacin, enoxacin, gatifloxacin, gemifloxacin, levofloxacin, lomefloxacin, moxifloxacin, norfloxacin, ofloxacin and trovafloxacin.

Sulfonamides include, but are not limited to, mafenide, prontosil, sulfacetamide, sulfamethizole, sulfanilamide, sulfasalazine, sulfisoxazole, trimethoprim, and co-trimoxazole (trimethoprim-sulfamethoxazole).

Tetracyclines include, but are not limited to, demeclocycline, doxycycline, minocycline, oxytetracycline and tetracycline.

Other antibiotics include arspenamine, chloramphenicol, clindamycin, lincomycin, ethambutol, fosfomycin, fusidic acid, furazolidone, isoniazid, linezolid, metronidazole, mupirocin, nitrofurantoin, platensimycin, pyrazinamide, quinupristin/dalfopristin, rifampin (rifampicin), tinidazole, etc.

In some embodiments, the composition can be a dentifrice composition comprising one or more of the compounds described herein. A “dentifrice” is a substance that is used to clean the teeth. It may be in the form of, e.g., a paste or powder. Commonly known dentifrices include toothpaste, mouthwash, chewing gum, dental floss, and dental cream. Other examples of dentifrices include toothpowder, mouth detergent, troches, dental or gingival massage cream, dental strips, dental gels, and gargle tablets. Examples of dentifrice compositions comprising toothpaste and mouthwash are found in U.S. Pat. No. 6,861,048 (Yu et al.); U.S. Pat. No. 6,231,836 (Takhtalian et al.); and U.S. Pat. No. 6,331,291 (Glance et al.); each of which are incorporated by reference herein in their entirety.

Coating compositions are also provided. A “coating” as used herein is generally known. Any of a variety of organic and aqueous coating compositions, with or without pigments, may be modified to contain one or more compounds described herein. Examples of suitable coating compositions include, for example, the coating compositions described in U.S. Pat. Nos. 7,109,262, 6,964,989, 6,835,459, 6,677,035, 6,528,580, and 6,235,812, each incorporated by reference herein in their entirety.

In some examples, coating compositions can comprise (in addition to one or more compounds described herein) a film-forming resin, an aqueous or organic solvent that disperses the resin; and, optionally, at least one pigment. Other ingredients such as colorants, secondary pigments, stabilizers and the like can be included if desired. The one or more biofilm modulating compounds described herein may be dissolved or dispersed in the solvent and/or resin, so that the compound(s) are dispersed or distributed on the substrate an article coated by the coating composition. The resin may comprise, for example, a polymeric material. A polymeric material is a material that is comprised of large molecules made from associated smaller repeating structural units, often covalently linked. Common examples of polymeric materials are unsaturated polyester resins, and epoxy resins.

Any suitable article can be coated, in whole or in part, with the coating compositions described herein. Suitable articles include, but are not limited to, automobiles and airplanes (including substrates such as wing and propeller surfaces for aerodynamic testing), vessel hulls

(including interior and exterior surfaces thereof), pressure vessels (including interior and exterior surfaces thereof), medical devices (e.g., implants), windmills, etc. Coating of the article with the composition can be carried out by any suitable means, such as by brushing, spraying, electrostatic deposition, dip coating, doctor blading, etc.

Devices

Also provided are medical devices that comprise a medical device substrate and an effective amount of a compound described herein either coating the substrate, or incorporated into the substrate. The effective amount of the compound can be an effective amount to prevent or inhibit growth of a biofilm on the medical device substrate.

“Medical device” as used herein refers to an object that is inserted or implanted in a subject or applied to a surface of a subject. Common examples of medical devices include stents, fasteners, ports, catheters, scaffolds and grafts. A “medical device substrate” can be made of a variety of biocompatible materials, including, but not limited to, metals, ceramics, polymers, gels, and fluids not normally found within the human body. Examples of polymers useful in fabricating medical devices include such polymers as silicones, rubbers, latex, plastics, polyanhydrides, polyesters, polyorthoesters, polyamides, polyacrylonitrile, polyurethanes, polyethylene, polytetrafluoroethylene, polyethylenetetrathalate, etc. Medical devices can also be fabricated using naturally-occurring materials or treated with naturally-occurring materials. Medical devices can include any combination of artificial materials, e.g., combinations selected because of the particular characteristics of the components. Medical devices can be intended for short-term or long-term residence where they are positioned. A hip implant is intended for several decades of use, for example. By contrast, a tissue expander may only be needed for a few months, and is removed thereafter.

Some examples of medical devices are found in U.S. Pat. No. 7,081,133 (Chinn et al.); U.S. Pat. No. 6,562,295 (Neuberger); and U.S. Pat. No. 6,387,363 (Gruskin); each incorporated by reference herein in their entirety.

Methods of Use

Methods of controlling biofilm formation on a substrate are disclosed, comprising the step of administering a compound described herein to a substrate in an amount effective to inhibit biofilm formation.

A “substrate” as used herein is a base on which an organism, such as those commonly found in biofilms, may live. The term “substrate,” as used herein, refers to any substrate, whether in an industrial or a medical setting, that provides or can provide an interface between an object and a fluid, permitting at least intermittent contact between the object and the fluid. A substrate,

as understood herein, further provides a plane whose mechanical structure, without further treatment, is compatible with the adherence of microorganisms. Substrates compatible with biofilm formation may be natural or synthetic, and may be smooth or irregular. Fluids contacting the substrates can be stagnant or flowing, and can flow intermittently or continuously, with laminar or turbulent or mixed flows. A substrate upon which a biofilm forms can be dry at times with sporadic fluid contact, or can have any degree of fluid exposure including total immersion. Fluid contact with the substrate can take place via aerosols or other means for air-borne fluid transmission.

Biofilm formation with health implications can involve those substrates in all health-related environments, including substrates found in medical environments and those substrates in industrial or residential environments that are involved in those functions essential to human well being, for example, nutrition, sanitation and the prevention of disease. Substrates found in medical environments include the inner and outer aspects of various instruments and devices, whether disposable or intended for repeated uses. Examples include the entire spectrum of articles adapted for medical use, including scalpels, needles, scissors and other devices used in invasive surgical, therapeutic or diagnostic procedures; implantable medical devices, including artificial blood vessels, catheters and other devices for the removal or delivery of fluids to patients, artificial hearts, artificial kidneys, orthopedic pins, plates and implants; catheters and other tubes (including urological and biliary tubes, endotracheal tubes, peripherally insertable central venous catheters, dialysis catheters, long term tunneled central venous catheters, peripheral venous catheters, short term central venous catheters, arterial catheters, pulmonary catheters, Swan-Ganz catheters, urinary catheters, peritoneal catheters), urinary devices (including long term urinary devices, tissue bonding urinary devices, artificial urinary sphincters, urinary dilators), shunts (including ventricular or arterio-venous shunts); prostheses (including breast implants, penile prostheses, vascular grafting prostheses, heart valves, artificial joints, artificial larynxes, otological implants), vascular catheter ports, wound drain tubes, hydrocephalus shunts, pacemakers and implantable defibrillators, and the like. Other examples will be readily apparent to practitioners in these arts. Substrates found in the medical environment also include the inner and outer aspects of pieces of medical equipment, medical gear worn or carried by personnel in the health care setting. Such substrates can include counter tops and fixtures in areas used for medical procedures or for preparing medical apparatus, tubes and canisters used in respiratory treatments, including the administration of oxygen, of solubilized drugs in nebulizers and of anesthetic agents. Also included are those substrates intended as biological barriers to infectious organisms in medical settings, such as gloves, aprons

and faceshields. Commonly used materials for biological barriers may be latex-based or non-latex based. Vinyl is commonly used as a material for non-latex surgical gloves. Other such substrates can include handles and cables for medical or dental equipment not intended to be sterile. Additionally, such substrates can include those non-sterile external substrates of tubes and other apparatus found in areas where blood or body fluids or other hazardous biomaterials are commonly encountered.

Substrates in contact with liquids are particularly prone to biofilm formation. As an example, those reservoirs and tubes used for delivering humidified oxygen to patients can bear biofilms inhabited by infectious agents. Dental unit waterlines similarly can bear biofilms on their substrates, providing a reservoir for continuing contamination of the system of flowing an aerosolized water used in dentistry. Sprays, aerosols and nebulizers are highly effective in disseminating biofilm fragments to a potential host or to another environmental site. It is especially important to health to prevent biofilm formation on those substrates from where biofilm fragments can be carried away by sprays, aerosols or nebulizers contacting the substrate.

Other substrates related to health include the inner and outer aspects of those articles involved in water purification, water storage and water delivery, and articles involved in food processing. Substrates related to health can also include the inner and outer aspects of those household articles involved in providing for nutrition, sanitation or disease prevention. Examples can include food processing equipment for home use, materials for infant care, tampons and toilet bowls. "Substrate" as used herein also refers to a living substrate, such as the inner ear of a patent.

Substrates can be smooth or porous, soft or hard. Substrates can include a drainpipe, glaze ceramic, porcelain, glass, metal, wood, chrome, plastic, vinyl, Formica® brand laminate, or any other material that may regularly come in contact with an aqueous solution in which biofilms may form and grow. The substrate can be a substrate commonly found on household items such as shower curtains or liners, upholstery, laundry, and carpeting.

A substrate on which biofilm preventing, removing or inhibiting is important is that of a ship hull. Biofilms, such as those of *Halomonas pacifica*, promote the corrosion of the hull of ships and also increase the roughness of the hull, increasing the drag on the ship and thereby increasing fuel costs. The biofilm can also promote the attachment of larger living structures such as barnacles on the ship hull. Fuel can account for half of the cost of marine shipping, and the loss in fuel efficiency due to biofilm formation is substantial.

Substrates on which biofilms can adhere include those of living organisms, as in the case of humans with chronic infections caused by biofilms, as discussed above. Biofilms can also form on the substrates of food contact surfaces, such as those used for processing seafood, and also on food products themselves. Examples of seafood products that may

5 have biofilm contamination include oysters. Human infections caused by the ingestion of raw oysters has been linked to *Vibrio vulnificus* bacterium. *Vibrio* bacteria attach to algae and plankton in the water and transfer to the oysters and fish that feed on these organisms.

Other examples of substrates or devices on which biofilms can adhere can be found in U.S. Pat. Nos. 5,814,668 and 7,087,661; and U.S. Pat. Application Publication Nos.
10 2006/0228384 and 2006/0018945, each of which is incorporated herein by reference in its entirety.

In some embodiments, methods of enhancing the effects of a biocide are disclosed, comprising the step of administering a compound described herein in combination with a biocide, the active compound being administered in an amount effective to enhance the effects of
15 the biocide.

“Administering” or “administration of” a compound described herein and/or biocide as used herein is inclusive of contacting, applying, etc. (e.g., contacting with an aqueous solution, contacting with a surface (e.g., a hospital surface such as a table, instrumentation, etc.)), in addition to providing to a subject (for example, to a human subject in need of treatment for a
20 microbial infection).

“Enhancing” the effects of a biocide by administering a compound described herein in combination with the biocide refers to increasing the effectiveness of the biocide, such that the microorganism killing and/or growth inhibition is higher at a certain concentration of the biocide administered in combination with the active compound than without. In some embodiments, a
25 bacteria or other microorganism is “sensitized” to the effects of a biocide, such that the bacteria or other microorganism that was resistant to the biocide prior to administering the compound described herein (e.g., little to none, or less than 20, 10, 5 or 1% are killed upon application) is rendered vulnerable to that biocide upon or after administering the compound (e.g., greater than 20, 30, 40, 50, 60, 70, 80, 90, or 95% or more are killed).

30 As used herein, the administration of two or more compounds (inclusive of the compounds described herein and biocides) “in combination” means that the two compounds are administered closely enough in time that the administration of or presence of one alters the biological effects of the other. The two compounds may be administered simultaneously (concurrently) or sequentially.

Simultaneous administration of the compounds may be carried out by mixing the compounds prior to administration, or by administering the compounds at the same point in time but at different anatomic sites or using different routes of administration, or administered at times sufficiently close that the results observed are indistinguishable from those achieved when the compounds are administered at the same point in time.

Sequential administration of the compounds may be carried out by administering, e.g., an active compound at some point in time prior to administration of a biocide, such that the prior administration of active compound enhances the effects of the biocide (e.g., percentage of microorganisms killed and/or slowing the growth of microorganisms). In some embodiments, an active compound is administered at some point in time prior to the initial administration of a biocide. Alternatively, the biocide may be administered at some point in time prior to the administration of an active compound, and optionally, administered again at some point in time after the administration of an active compound.

Also provided herein are methods for controlling biofilm formation on a substrate.

Methods for controlling biofilm formation on a substrate can comprise contacting the substrate with a compound described herein in an amount effective to inhibit biofilm formation.

The biofilm can comprise Gram-positive bacteria or Gram-negative bacteria. In some embodiments, the biofilm can comprise Gram-positive bacteria. Examples of Gram-positive bacteria affected by compounds described herein include, but are not limited to, bacteria of the genera *Listeria*, *Staphylococcus*, *Streptococcus*, *Bacillus*, *Corynebacterium*, *Peptostreptococcus*, and *Clostridium*. For example, the bacteria can include *Listeria monocytogenes*, *Staphylococcus aureus*, *Streptococcus pyogenes*, *Streptococcus pneumoniae*, *Bacillus cereus*, *Bacillus anthracis*, *Clostridium botulinum*, *Clostridium perfringens*, *Clostridium difficile*, *Clostridium tetani*, *Corynebacterium diphtheriae*, *Corynebacterium ulcerans*, and *Peptostreptococcus anaerobius*. Other examples of Gram-positive bacteria include, for example, bacteria of the genera *Actinomyces*, *Propionibacterium*, *Nocardia* and *Streptomyces*.

In some embodiments, the biofilm can comprise Gram-negative bacteria. Examples of Gram-negative bacteria affected by compounds described herein include, but are not limited to, bacteria of the genera *Escherichia*, *Salmonella*, *Vibrio*, *Helicobacter*, *Pseudomonas*, *Bordetella*, *Vibrio*, *Haemophilus*, *Halomonas*, and *Acinetobacter*. For example, the bacteria can include *Pseudomonas aeruginosa*, *Bordetella pertussis*, *Vibrio vulnificus*, *Haemophilus influenzae*, *Halomonas pacifica*, and *Acinetobacter baumannii*. Other examples of Gram-negative bacteria include, for example, bacteria of the genera *Klebsiella*, *Proteus*, *Neisseria*,

Helicobacter, Brucella, Legionella, Campylobacter, Francisella, Pasteurella, Yersinia, Bartonella, Bacteroides, Streptobacillus, Spirillum, Moraxella and Shigella.

Also provided are methods for treating chronic bacterial infections in a subject in need thereof. These methods can comprise administering a compound described herein to a subject in an amount effective to inhibit, reduce, or remove a biofilm component of said chronic bacterial infection. “Treating” as used herein refers to any type of activity that imparts a benefit to a patient afflicted with a disease, including improvement in the condition of the patient (e.g., in one or more symptoms), delay in the progression of the disease, delay in onset of the disease, etc.

A “chronic bacterial infection” is a bacterial infection that is of a long duration or frequent recurrence. For example, a chronic middle ear infection, or otitis media, can occur when the Eustachian tube becomes blocked repeatedly due to allergies, multiple infections, ear trauma, or swelling of the adenoids. The definition of “long duration” will depend upon the particular infection. For example, in the case of a chronic middle ear infection, it may last for weeks to months. Other known chronic bacterial infections include urinary tract infection (most commonly caused by *Escherichia coli* and/or *Staphylococcus saprophyticus*), gastritis (most commonly caused by *Helicobacter pylori*), respiratory infection (such as those commonly afflicting patients with cystic fibrosis, most commonly caused by *Pseudomonas aeruginosa*), cystitis (most commonly caused by *Escherichia coli*), pyelonephritis (most commonly caused by *Proteus* species, *Escherichia coli* and/or *Pseudomonas* species), osteomyelitis (most commonly caused by *Staphylococcus aureus*, but also by *Escherichia coli*), bacteremia, skin infection, rosacea, acne, chronic wound infection, infectious kidney stones (can be caused by *Proteus mirabilis*), bacterial endocarditis, and sinus infection. A common infection afflicting pigs is atrophic rhinitis (caused by *Bordetella* species, e.g. *Bordetella rhinitis*).

Also disclosed is a method of clearing a preformed biofilm from a substrate comprising the step of administering an effective amount of a compound described herein to said substrate, wherein said effective amount will reduce the amount of said biofilm on said substrate.

“Preformed biofilm” is a biofilm that has begun to adhere to a substrate. The biofilm may or may not yet be fully formed.

Also provided are methods of treating subjects infected with a bacterium. Methods of treating a subject infected with a bacterium can comprise administering to the subject a therapeutically effective amount of a compound described herein. In some embodiments, the bacterium can comprise a Gram-positive bacterium. Examples of Gram-positive bacteria affected by the compounds described herein include, but are not limited to, bacteria of the genera *Listeria, Staphylococcus, Streptococcus, Bacillus, Corynebacterium, Peptostreptococcus,*

and *Clostridium*. For example, the bacterium can include *Listeria monocytogenes*, *Staphylococcus aureus*, *Streptococcus pyogenes*, *Streptococcus pneumoniae*, *Bacillus cereus*, *Bacillus anthracis*, *Clostridium botulinum*, *Clostridium perfringens*, *Clostridium difficile*, *Clostridium tetani*, *Corynebacterium diphtheriae*, *Corynebacterium ulcerans*, and

5 *Peptostreptococcus anaerobius*. Other examples of Gram-positive bacteria include, for example, bacteria of the genera *Actinomyces*, *Propionibacterium*, *Nocardia* and *Streptomyces*. In certain embodiments, the bacterium can include *Staphylococcus aureus* (methicillin sensitive), *Staphylococcus aureus* (methicillin resistant), *Staphylococcus aureus* (vancomycin resistant), *Streptococcus pneumoniae* (penicillin sensitive), *Streptococcus pneumoniae* (penicillin resistant), *Staphylococcus epidermidis* (multiple drug resistant), *Enterococcus*
10 *faecalis* (vancomycin sensitive), *Enterococcus faecium* (vancomycin resistant), and/or *Haemophilus influenzae*.

In some embodiments, the bacterium can comprise Gram-negative bacteria. Examples of Gram-negative bacteria affected by the oxazolidinone derivatives described herein include, but
15 are not limited to, bacteria of the genera *Escherichia*, *Salmonella*, *Vibrio*, *Helicobacter*, *Pseudomonas*, *Bordetella*, *Vibrio*, *Haemophilus*, *Halomonas*, and *Acinetobacter*. For example, the bacteria can include *Pseudomonas aeruginosa*, *Bordetella pertussis*, *Vibrio vulnificus*, *Haemophilus influenzae*, *Halomonas pacifica*, and *Acinetobacter baumannii*. Other examples of Gram-negative bacteria include, for example, bacteria of the genera *Klebsiella*, *Proteus*,
20 *Neisseria*, *Helicobacter*, *Brucella*, *Legionella*, *Campylobacter*, *Francisella*, *Pasteurella*, *Yersinia*, *Bartonella*, *Bacteroides*, *Streptobacillus*, *Spirillum*, *Moraxella* and *Shigella*. In some embodiments, the bacterium can comprise a Gram-negative bacterium. For example, the bacterium can include *Salmonella*, *E. Coli*, *Acinetobacter baumannii*, *Pseudomonas aeruginosa* or *Klebsiella pneumoniae*.

25 By way of non-limiting illustration, examples of certain embodiments of the present disclosure are given below.

EXAMPLES

Materials and Methods

THF was purified using an alumina filtration system. Aldehydes were purchased from a
30 commercial chemical company and used as received. Reactions were monitored by TLC analysis (pre-coated silica gel 60 F₂₅₄ plates, 250 mm layer thickness) and visualization was accomplished with a 254 nm UV light and by staining with a KMnO₄ solution (1.5 g of KMnO₄, 10 g of K₂CO₃, and 1.25 mL of a 10% NaOH solution in 200 mL of water). Reactions were also monitored by LC-MS (2.6 mm C18 50 x 2.10 mm column). Flash chromatography on SiO₂ was

used to purify the crude reaction mixtures and performed on a flash system utilizing pre-packed cartridges and linear gradients. Melting points were determined using a capillary melting point apparatus. Infrared spectra were determined on a FT/IR spectrometer. ^1H and ^{13}C NMR spectra were obtained on a 400 MHz instrument in CDCl_3 unless otherwise noted. Chemical shifts were reported in parts per million with the residual solvent peak used as an internal standard ($\text{CDCl}_3 = 7.26$ ppm for ^1H and 77.16 ppm for ^{13}C). ^1H NMR spectra were run at 300, 400, or 700 MHz and are tabulated as follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, p = pentet, m = multiplet, bs = broad singlet, dt = doublet of triplet, tt = triplet of triplet), number of protons, and coupling constant(s). ^{13}C NMR spectra were run at 100 or 175 MHz using a proton-decoupled pulse sequence with a d_1 of 0 seconds unless otherwise noted, and are tabulated by observed peak. High-resolution mass spectra were obtained on an ion trap mass spectrometer using heated electrospray ionization (HESI).

General procedure for the Synthesis of 2-Oxo-3-Propanoic Acids

2-oxo-3-propanoic acids were prepared according to established literature procedures. In brief: A slurry of aldehyde (1 equiv.), sodium acetate (1.3 equiv.) and *N*-acetyl glycine (1.3 equiv.) in acetic anhydride (5 equiv.) was heated to 140 °C for 1 h. The reaction mixture was quenched with ice (~20 mL) with vigorous stirring and cooled in an ice bath. The resulting precipitate was collected by vacuum filtration to afford the azlactone, which was used without further purification. The azlactone was suspended in 3 M HCl and heated at reflux until complete hydrolysis was observed by LC-MS (typically ~3 h). The reaction mixture was cooled in an ice bath to facilitate crystallization. The resulting solid was isolated by vacuum filtration and dried extensively under high vacuum to provide the desired acid as a solid. This solid can be recrystallized from benzene if necessary. Analytical data was consistent with previously reported data.


General procedure for the Synthesis of α,α -Dichloroimines

α,α -dichloroimines were prepared according to an established literature procedure. In brief: To a solution of aldehyde in dry dichloromethane (0.2 M) was added dropwise *t*-butyl amine (1.0 equiv.) with vigorous stirring. To this solution was added anhydrous magnesium sulfate (~3 equiv.) and the mixture was stirred vigorously for ~12 h at room temperature. The MgSO_4 was removed by vacuum filtration and the filtrate was concentrated *in vacuo*. The residue was dissolved in CCl_4 (0.5 M) and cooled to 0 °C, before addition of *N*-chlorosuccinimide (2.1 equiv.) in four portions over the course of 2 hours. This mixture was stirred at room temperature for 24 h. The mixture was cooled to 0 °C and filtered through a fine (4-5.5 μm) sintered glass frit funnel to remove succinimide. The filtrate was concentrated *in*

vacuo and dried extensively under high vacuum. The resulting α,α -dichloroimines were used without purification and can be stored under inert atmosphere at $-30\text{ }^{\circ}\text{C}$.

Synthesis of 5-Benzylidene-4-Oxazolidinones


General Procedure: To a solution of arylpyruvic acid ($\sim 0.5\text{ mmol}$) in dry THF ($\sim 0.5\text{ M}$) at $0\text{ }^{\circ}\text{C}$ was added dropwise oxalyl chloride (1.15 equiv.) followed by *N,N*-dimethylformamide (0.10 equiv.). The solution was stirred at $0\text{ }^{\circ}\text{C}$ for 2 hours before the reaction mixture was concentrated under reduced pressure (directly through the septum using a needle). The crude acid chloride was dissolved in dry CHCl_3 (0.5 M) and added dropwise under inert atmosphere to a solution of crude *t*-butyl α,α -dichloroimine in dry CHCl_3 (0.5 M) at $0\text{ }^{\circ}\text{C}$. This mixture was warmed slowly to room temperature and stirred overnight. The reaction mixture was concentrated *in vacuo*. The residue was dissolved in trifluoroacetic acid and heated to $50\text{ }^{\circ}\text{C}$ until complete conversion was observed by LC-MS (typically 2-4 h). The reaction mixture was concentrated *in vacuo* and purified by reverse-phase flash chromatography ($\text{SiO}_2\text{-C18}$; $\text{CH}_3\text{CN}/\text{H}_2\text{O}$).



(1)

(Z)-2-(1,1-dichloropentyl)-5-(4-(trifluoromethyl)benzylidene)oxazolidin-4-one (1).


25 mg (22%) isolated as a white crystalline solid. ^1H NMR: (400 MHz, CDCl_3) δ 8.93 (s, 1H), 7.74 (d, $J = 7.79\text{ Hz}$, 2H), 7.64 (d, $J = 7.81\text{ Hz}$, 2H), 6.35 (s, 1H), 5.80 (s, 1H), 2.33 (m, 1H), 2.20 (m, 1H), 1.78 (m, 2H), 1.46 (m, 2H), 0.99 (t, $J = 7.19$, 3H).



(2)


(Z)-2-(1,1-dichloro-2-phenylethyl)-5-(4-(trifluoromethyl)benzylidene)oxazolidin-4-one (2). 18 mg (10%) isolated as a white crystalline solid. ^1H NMR: (400 MHz, CDCl_3) δ 7.76

(d, $J = 8.35$ Hz, 2H), 7.67 (d, $J = 8.39$ Hz, 2H), 7.43 (m, 2H), 7.38 (m, 3H), 6.38 (s, 1H), 5.71 (s, 1H), 3.69 (s, 2H).




(3)

(Z)-2-(1,1-dichlorononyl)-5-(4-(trifluoromethyl)benzylidene)oxazolidin-4-one (3). 23 mg (24%) isolated as an off-white solid. ^1H NMR: (400 MHz, CDCl_3) δ 8.94 (s, 1H), 7.74 (d, $J = 7.84$ Hz, 2H), 7.64 (d, $J = 7.88$ Hz, 2H), 6.35 (s, 1H), 5.80 (s, 1H), 2.33 (m, 1H), 2.20 (m, 1H), 1.79 (m, 2H), 1.41 (m, 2H), 1.35-1.29 (m, 8H), 0.99 (t, $J = 6.61$, 3H).




(4)

(Z)-2-(1,1-dichloroethyl)-5-(4-(trifluoromethyl)benzylidene)oxazolidin-4-one (4). 18 mg (25%) isolated as a white crystalline solid. ^1H NMR: (400 MHz, $(\text{CD}_3)_2\text{CO}$) δ 9.44 (s, 1H), 7.93 (d, $J = 8.07$ Hz, 2H), 7.75 (d, $J = 7.76$ Hz, 2H), 6.28 (s, 1H), 6.07 (s, 1H), 2.28 (s, 3H).




(5)

(Z)-2-(1,1-dichlorobut-3-yn-1-yl)-5-(4-(trifluoromethyl)benzylidene)oxazolidin-4-one (5). 46 mg (51%) isolated as an off-white solid. ^1H NMR: (400 MHz, CDCl_3) δ 8.69 (s, 1H), 7.74 (d, $J = 7.85$ Hz, 2H), 7.64 (d, $J = 7.86$ Hz, 2H), 6.38 (s, 1H), 6.06 (s, 1H), 3.37 (s, 2H), 2.34 (s, 1H).



(6)


5 **(Z)-5-benzylidene-2-(1,1-dichloropentyl)oxazolidin-4-one (6).** 19 mg (28%) isolated as a white solid. ^1H NMR: (400 MHz, CDCl_3) δ 8.83 (s, 1H), 7.65 (d, $J = 7.19$ Hz, 2H), 7.39 (m, 2H), 7.30 (m, 1H), 6.34 (s, 1H), 5.77 (s, 1H), 2.32 (m, 1H), 2.20 (m, 1H), 1.77 (m, 2H), 1.44 (m, 2H), 0.99 (t, $J = 7.34$, 3H).



(7)

(Z)-2-(tert-butyl)-5-(4-(trifluoromethyl)benzylidene)oxazolidin-4-one (7).


10 Synthesized via a previously reported procedure⁵. 46 mg (96%) isolated as a white solid. ^1H NMR: (400 MHz, CDCl_3) δ 9.02 (s, 1H), 7.74 (d, $J = 8.31$ Hz, 2H), 7.62 (d, $J = 8.33$ Hz, 2H),
15 6.22 (s, 1H), 5.31 (s, 1H), 1.04 (s, 9H).



(8)

20 **(Z)-2-pentyl-5-(4-(trifluoromethyl)benzylidene)oxazolidin-4-one (8).** Previously reported⁵. 8.7 mg (32%) isolated as a brown oil: ^1H NMR (400 MHz, CDCl_3) δ 8.92 (s, 1H), 7.76 (d, 2H, $J = 8.0$ Hz), 7.61 (d, 2H, $J = 8.1$ Hz), 6.26 (s, 1H), 5.71 (bs, 1H), 1.88 (s, 2H), 1.71 – 1.29 (m, 6H), 0.91 (t, 3H, $J = 6.6$ Hz); ^{13}C NMR (100 MHz, CDCl_3) δ 165.8, 145.3, 137.1, 129.3,
25 125.6, 122.9, 102.5, 89.7, 36.4, 31.5, 22.8, 22.6, 14.0. IR (thin film, cm^{-1}): 3213, 2930, 1714,

1324, 1117, 861; HRMS (HESI) m/z calculated for $C_{16}H_{19}F_3NO_2$ $[M+H]^+$ 312.1217, found 312.1214; R_f = 0.27 (40% EtOAc/hexanes).




(9)

5

***N*-hexyl-2-oxo-3-(4-(trifluoromethyl)phenyl)propanamide (9).** To a solution of 2-oxo-3-(4-(trifluoromethyl)phenyl)propanoic acid (0.232 g, 1.0 mmol) in THF (10 mL; 0.1 M) at 0 °C was added *N*-(3-dimethylaminopropyl)-*N'*-ethylcarbodiimide hydrochloride (0.2322 g, 1.20 mmol, 1.2 equiv.), 1-hydroxybenzotriazole hydrate (0.1843 g, 1.20 mmol, 1.2 equiv.) and *N,N*-diisopropylethylamine (0.355 mL, 2.0 mmol, 2.0 equiv.). This mixture was stirred at 0 °C for several minutes before hexylamine (0.146 mL, 1.0 mmol, 1.0 equiv.) was added and the resulting solution was allowed to warm to room temperature with vigorous stirring. After 14 hours the reaction mixture was diluted with Et₂O and washed successively with 3 M HCl (10 mL X2), sat. NaHCO₃ (10 mL X3), H₂O (20 mL) and brine. The organic layer was dried over MgSO₄, filtered and concentrated *in vacuo*. The residue was purified by flash chromatography (SiO₂, EtOAc/hexanes). 116 mg (43%) isolated as an off-white solid. ¹H NMR: (400 MHz, CDCl₃) δ 7.87 (d, *J* = 7.82 Hz, 2H), 7.67 (d, *J* = 7.81 Hz, 2H), 4.58 (s, 2H), 3.60 (m, 2H), 2.33 (m, 1H), 2.20 (m, 1H), 1.83 (m, 2H), 1.58 (m, 4H), 1.17 (m, 3H).

20




(10)

(±)-Synoxazolidinone A (10). As previously reported⁶: 10.9 mg (88%) isolated as a colorless oil: ¹H NMR (400 MHz, CD₃OD) δ 7.89 (s, 2H), 6.08 (s, 1H), 5.91 (d, *J* = 2.4 Hz, 1H), 4.30 (dt, *J* = 11.0, 2.6 Hz, 1H), 3.86 (s, 3H), 3.56 – 3.35 (m, 2 H), 2.32 – 2.22 (m, 1H), 2.10 – 1.99 (m, 1 H); ¹³C NMR (100 MHz, CD₃OD) δ 165.6, 158.8, 154.5, 146.5, 134.1, 119.1, 100.6,

25

90.3, 61.7, 61.2, 39.5, 32.3. HRMS (HESI) m/z calculated for $C_{15}H_{16}Br_2ClN_4O_3$ [M-H] 492.9283, found 492.9290.



(11)

(Z)-2-(1,1-di-Chloropentyl)-5-(4-methoxybenzylidene)oxazolidin-4-one (11). 47.5 mg (27%) isolated as a brown crystalline solid. ^1H NMR: (400 MHz, $CDCl_3$) δ 8.21 (bs, 1H), 7.61 (d, J = 7.59, 2H), 6.92 (d, J = 6.91, 2H), 6.29 (s, 1H), 5.73 (s, 1H), 3.83 (s, 3H), 2.31 (dt, J = 15.89, 7.33, 1H), 2.20 (dt, J = 14.32, 7.51, 1H), 1.76 (dt, J = 15.72, 7.71, 2H), 1.43 (m, 2H) 0.98 (t, J = 7.33, 3H). ^{13}C NMR: (175 MHz, $CDCl_3$) δ 165.2, 159.7, 141.1, 131.1, 114.3, 105.3, 94.0, 90.8, 55.5, 41.1, 26.5, 22.4, 14.0. IR ν_{max} (cm $^{-1}$): 3199, 3069, 2959, 2931, 2872, 2836, 1717, 1606, 1511, 1349, 1252, 1176, 1030. mp 146-148 °C ($CDCl_3$). HRMS (HESI) m/z calculated for $C_{16}H_{19}Cl_2NO_3$ [M-H] 344.08148, found 344.08179.

Biological Characterization of Compounds 1-11

General Information. Methicillin-resistant *Staphylococcus aureus* (MRSA) strains were obtained from the Laboratory of Professor Christian Melander (NCSU) ATCC (33591, BAA 44, BAA 1685, BAA 1770, BAA 43 300) and colonies were grown on solid media as instructed. Mueller-Hinton broth (MHB, 211443-BD), tryptic soy broth (TSB, Remel: R455052) and D-glucose (CAS: 492-62-6) were purchased from Fisher Scientific. Tryptic soy agar (TSA, cat. # 22091) and Linezolid (cat. # P70014) were purchased from Sigma-Aldrich. Bacteria for biofilm inhibition and dispersion assays were cultured overnight in TSBG (tryptic soy broth with 0.5% glucose supplement). All assays were run in duplicate and repeated at least two separate times for MIC assays and at least four separate times for biofilm inhibition and dispersion assays. All compounds were dissolved molecular biology grade DMSO as 100 mM stock solutions and further diluted to 10 and 1 mM stock solutions as needed. Optical densities were measured using a Thermo Scientific Genesys 20 spectrophotometer. Data for biofilm inhibition and dispersion assays was collected using a BioTek ELx808 Microplate Reader. All graphs were generated and analyzed using GraphPad Prism 7.

Broth microdilution protocol for minimum inhibition concentration (MIC) determination. Studies were performed using the standard method prescribed by the Clinical

and Laboratory Standards Institute (CLSI) M07-A8, Vol. 29 (2), which is hereby incorporated herein by reference. Briefly, fresh Mueller–Hinton broth (MHB) ~ 3 ml, was inoculated (5×10^5 CFU mL⁻¹) with MRSA (ATCC 33591) methicillin-resistant *Staphylococcus aureus*. The resulting bacterial suspension was aliquoted (1 mL) into culture tubes and test compound (10 mM DMSO stock solution) was added to reach the final concentration of the interest. Bacteria not treated with the antimicrobial compound served as the control. Rows 2–12 of a 96-well microtiter plate were filled with remaining bacterial subcultures. The samples containing test compound were aliquoted (200 µL) into the first row wells of the microtiter plate (2 wells per compound). Row 1 wells were mixed 6 – 8 times and 100 µL was transferred down to row 2. Row 2 wells were mixed 6 – 8 times, followed by a 100 µL transfer from row 2 down to row 3. The rest of the rows of the plate were serially diluted in similar fashion. The plate was covered with sealing tape for 96-well plates (ThermoFisher) and incubated under stationary conditions at 37 °C. A duplicate of the plate was prepared. The lowest concentration of test compound at which no visible growth of bacteria occurred – minimum inhibitory concentration (MIC) values were recorded after 16 h.

Biofilm Inhibition Assay. Studies were performed using the standard method described in S. A. Rogers and C. Melander, *Angew Chem Int Ed*, 2008, **47**, 5229-5231. Briefly, biofilm inhibition assays were performed by taking an overnight culture of bacterial strain and subculturing it at an OD₆₀₀ of 0.01 into the necessary growth liquid medium (LB for *A. baumannii*, LBNS for *P. aeruginosa*, Stainer-Scholte medium that was supplemented with 10 µL/mL of 100X nutrient complex for *B. bronchiseptica* and TSB w/0.3% glucose for *S. aureus*) for the strain. The compound being tested was then added at a predetermined concentration and then aliquoted (100 µL) into the wells of a 96-well PVC microtiter plate (wells not used for samples are filled with 100 µL of de-ionized water). Plates were then wrapped in GLAD Press n^o Seal and incubated under stationary conditions at 37° C. After 24 hours, the media was discarded from the wells and the plates were washed thoroughly with tap water. Plates were then stained with 100 µL of 0.1% solution of crystal violet (CV) and then incubated at an ambient temperature for 30 minutes. Sample plates were then washed with tap water again and the remaining stain was solubilized with 200 µL of 95% ethanol. Biofilm inhibition was quantitated by measuring the OD₅₄₀ for each well by transferring 125 µL of the solubilized CV stain into a polystyrene microtiter dish for analysis. Biofilm inhibition was quantified by measuring the OD₅₄₀ of each well and calculated as a percentage of the control (no compound); a negative control lane wherein no biofilm was formed served as a background and was subtracted out.

Percent inhibition was then plotted against concentration in Prism 7. Each of the four experiments were plotted separately and analyzed by a normalized nonlinear regression. The IC₅₀ values reported represent an arithmetic mean of the four IC₅₀ values. Biofilm data represent four separate experiments, with each experiment performed in duplicate (average of 8 data points for each concentration tested, unless otherwise noted)

Biofilm Dispersion Assay. Studies were performed using the standard method described in J. J. Richards, T. E. Ballard and C. Melander, *Org Biomol Chem*, 2008, **6**, 1356-1363. Briefly, dispersion assays were performed by taking an overnight culture of bacterial strain and subculturing it at an OD₆₀₀ of 0.01 into the necessary growth liquid medium. The resulting bacterial suspension was aliquoted (100 µL) into the wells of a 96-well PVC microtiter plate. Plates were then wrapped in GLAD Press n' Seal followed by an incubation under stationary conditions at an ambient temperature. After 24 hours, the media was discarded from the wells and the plates were washed thoroughly with tap water. Predetermined concentrations of the test compound were then made in the same medium used to initially grow the biofilms and then aliquoted (100 µL) into the wells of the 96-well PVC microtiter plate with the established biofilms. Plates were then wrapped in GLAD Press n' Seal and incubated under stationary conditions at 37° C. After 24 hours, the media was discarded from the wells and the plates were washed thoroughly with tap water. Plates were then stained with 100 µL of 0.1% solution of crystal violet (CV) and then incubated at room temperature for 30 minutes. Plates were then washed with tap water again and the remaining stain was solubilized with 200 µL of 95% ethanol. Biofilm dispersion was quantitated by measuring the OD₅₄₀ for each well by transferring 125 µL of the solubilized CV stain into a polystyrene microtiter dish for analysis. Biofilm inhibition was quantified by measuring the OD₅₄₀ of each well and calculated as a percentage of the control (no compound), a negative control lane wherein no biofilm was formed served as a background and was subtracted out.

Percent dispersion was then plotted against concentration in Prism 7. Each of the four experiments were plotted separately and analyzed by a normalized nonlinear regression. The IC₅₀ values reported represent an arithmetic mean of the four IC₅₀ values. Biofilm data represent four separate experiments, with each experiment performed in duplicate (average of 8 data points for each concentration tested, unless otherwise noted)

Discussion

The biological activity of the Compounds **1-11** was investigated. Table 1 includes a summary of the biological activity of Compounds **1-10**.

Table 1. Summary of the activity of Compounds **1-10**.

Compound	Antimicrobial Activity MIC ($\mu\text{g/mL}$)		Biofilm Inhibition IC_{50} (μM)	Biofilm Dispersion IC_{50} (μM)
	MRSA ATCC 33591	MRSA ATCC BAA-44	MRSA ATCC BAA-44	MRSA ATCC BAA-44
1	12	12	1.0	5.7
2	6	6	1.4	4.3
3	>128	>128	1.7	6.6
4	32	32	3.6	5.0
5	16	16	1.9	6.0
6	64	64	3.2	5.3
7	128	128	7.3	9.2
8	16	16	7.3	ND
9	>128	>128	>20	>20
10	10	10	27	>20

Table 2 includes the minimum inhibitory concentrations (MICs) for compounds 1-11 against MRSA (ATCC BAA-44). **1** exhibited similar antibacterial activity to that of **10**.

- Antimicrobial activity was completely abolished with a change from an n-butyl side chain (**1**) to an n-octyl side chain (**3**). Shortening the side chain from n-butyl (**1**) to methyl (**4**) resulted in significantly reduced activity. Conversely, a change from an n-butyl side chain (**1**) to a benzyl side chain (**2**) resulted in a 2-fold enhancement of the MIC, from 12 mg mL⁻¹ to 6 mg mL⁻¹. Inclusion of a terminal alkyne in the side chain (**5**) resulted in somewhat reduced activity compared to **1**. It was postulated that the electron-withdrawing trifluoromethyl substituent on the aromatic ring was important for the antimicrobial activity of the 2-dichloroalkyl-5-benzylidene-4-oxazolidinones. This was supported by the significantly diminished activity of **6** and **11**, both bearing an electron-rich aromatic ring. Further, a direct comparison of the antimicrobial activity of **4** to that of **7** reveals the importance of the dichloromethylene moiety for potency, whereby replacing the two chlorine atoms (**4**) with methyl groups (**7**) results in a 4-fold reduction in antimicrobial activity. In contrast, replacing the chlorine atoms (**1**) with hydrogen atoms (**8**) led to only a slight reduction in MIC, suggesting the benefit of the chlorine atoms is a result of the polar substituents rather than simply steric bulk. Finally, **9** exhibited no antimicrobial activity, illustrating the importance of the 4-oxazolidinone core.

Table 2. Biological activity of 5-benzylidene-4-oxazolidinones **1-11** against MRSA (ATCC BAA 44).

Cpd	MIC ($\mu\text{g/mL}$)	% Biofilm Inhibition (5 μM)	% Biofilm Inhibition (40 μM)	% Biofilm Dispersion (5 μM)	% Biofilm Inhibition (40 μM)
1	12	89	-	59	87
2	6	82	-	57	69
3	>128	68	75	19	19
4	32	55	-	50	-
5	16	64	-	63	-
6	64	51	-	14	26
7	128	31	51	5.7	31
8	64	17	53	-	-
9	>128	24	41	-24	-6.5
10	10	-	-	-	-
11	>128	39	52	49	58

The activity of Compounds **1-11** against bacterial biofilms was also evaluated. Biofilm inhibition assays were carried out according to the established crystal violet staining protocol. The results of these studies are summarized in Table 2. For these studies, we initially explored the percent inhibition of biofilm formation compared to an untreated control and further defined IC_{50} values for the most potent compounds.

Initial results from biofilm inhibition assays (MRSA ATCC BAA-44) with **10** revealed no biofilm inhibition activity up to 20 μM , followed by moderate inhibition at 40 and 80 μM . The observed activity did not appear to be dose-dependent. Compounds **1**, **2**, and **3** exhibited dose-dependent biofilm inhibition at concentrations well below their MIC. Additionally, **1** inhibited 89% and **2** inhibited 82% of biofilm formation at 5 μM , correspond IC_{50} values of 0.78 μM and 1.2 μM respectively. It is important to highlight that the range of concentrations tested directly correlated with the activity observed and the MIC of the compounds to avoid testing at concentrations significantly above the threshold where bacterial growth was greatly impacted. The impact of the relative size of the substituent on the aminal carbon of the 4-oxazolidinone was also investigated. It was determined that small to medium aliphatic substituents are more advantageous at this position.

Compound **4**, for example, exhibited a reduction in activity compared to **1** as was also observed for alkyne **5** to a lesser extent. In addition to the alkyl chain length, the electron deficient aromatic ring also seems to play a role in the biofilm inhibition potency (as was observed in the antimicrobial activity), whereby replacing the 4-trifluoromethyl substituent with a hydrogen atom reduced the activity significantly (**6**) and a methoxy substituent (**11**) resulted in <50% biofilm inhibition at 5 μM . The dichloromethylene moiety also plays a

significant role in the observed activity. Replacing the two chlorine atoms (**4**) with methyl groups (**7**) reduced the activity by 3-fold, reinforcing the advantage of the electronegative chlorine atoms. Similarly, substituting the two chlorine atoms (**1**) with hydrogen atoms (**8**) resulted in a 5-fold reduction in biofilm inhibition activity. Finally, secondary α -oxoamide **9** exhibited only modest biofilm activity, even at 40 μ M, affirming the importance of the 4-oxazolidinone for biofilm modulating properties.

Table 3. Antibiofilm activity of Compounds **1** and **2** against relevant MRSA strains.

Cpd		MRSA Strain		
		43300	1685	1770
1	MIC (μg/mL)	8	16	16
	% Biofilm Inhibition (5/40 μM)	59/54	45/66	49/66
	% Biofilm Dispersion (5/40 μM)	23/63	24/61	52/46
2	MIC (μg/mL)	8	8	8
	% Biofilm Inhibition (5/40 μM)	41/63	19/17	3/-16
	% Biofilm Dispersion (5/40 μM)	37/-	15/-	29/-

The activity of this panel of 4-oxazolidinones against pre-formed biofilms was also evaluated using an established crystal violet staining protocol. Percent inhibition values are shown in Table 2. Compound **1** resulted in 59% dispersion of pre-formed biofilm at 5 μ M and 87% dispersion at 40 μ M (IC_{50} = 4.7 μ M), while **2** displayed 57% dispersion at 5 μ M, although a maximum dispersion of 69% was observed at 40 μ M.

The antibacterial and anti-biofilm properties of **1** and **2** were also evaluated against three additional MRSA strains (Table 3, ATCC BAA 43 300, 1685, and 1770). Both **1** and **2** exhibited modest biofilm inhibition activity against MRSA strains BAA 43 300, 1685 and 1770 as compared to strain BAA-44. The efficacy of **1** was somewhat reduced against strain 43 300 and 1770. **2** exhibited slightly lower activity against strains 43 300 and 1685, although virtually no activity against strain 1770. On the other hand, biofilm dispersion efficacy of **1** was significantly reduced against MRSA strain BAA 43 300 and 1685, whereas **2** exhibited no dose-dependent dispersion activity against strain 43 300. Further studies will evaluate the efficacy of these 4-oxazolidinones on a larger panel of Gram-positive pathogens.

Analysis of the growth curves of **1** and **2** reveal substantial inhibition of growth in the first 8 hours by **1** at 1 μ M and 5 μ M. Although the final cellular density of the culture was

similar to that of the untreated control, the delayed growth could account, in part, for the observed biofilm inhibition activity. On the other hand, the growth curve of **2** showed modest deviation from the untreated control at 1 μ M and moderate growth inhibition in the first 8 hours at 5 μ M, indicating minimal inhibition of the growth of planktonic bacteria by this 4-oxazolidinone at optimal biofilm inhibition concentrations. It is worth noting that antimicrobial activity alone does not provide anti-biofilm activity, particularly in the case of dispersion where clinically employed antibiotics possess 10–1000x decreased efficacy, highlighting a unique aspect of the small molecules reported herein. Finally, lysis of red blood cells by compounds **1**, **2**, and **3** was evaluated. **1** and **2** lysed <1% of red blood cells at 100 μ M, while **3** lysed <1% of red blood cells at 20 μ M and 7% of red blood cells at 100 μ M.

In summary, the 2-dichloroalkyl-5-benzylidene-4-oxazolidinones described herein are modulators of MRSA biofilms. As described above, a series of simplified analogues were synthesized and their biofilm inhibition and dispersal activity was evaluated. Through structure–activity analyses, it appears that (1) electron-withdrawing substituents on the benzylidene moiety are important for antibiofilm potency, (2) the 4-oxazolidinone core is important for biological activity and (3) the dichloromethylene functionality improves biofilm activity.

The compounds, compositions, and methods of the appended claims are not limited in scope by the specific compounds, compositions, and methods described herein, which are intended as illustrations of a few aspects of the claims. Any compounds, compositions, and methods that are functionally equivalent are intended to fall within the scope of the claims. Various modifications of the compounds, compositions, and methods in addition to those shown and described herein are intended to fall within the scope of the appended claims. Further, while only certain representative compounds, compositions, and method steps disclosed herein are specifically described, other combinations of the compounds, compositions, and method steps also are intended to fall within the scope of the appended claims, even if not specifically recited. Thus, a combination of steps, elements, components, or constituents may be explicitly mentioned herein or less, however, other combinations of steps, elements, components, and constituents are included, even though not explicitly stated.


The term “comprising” and variations thereof as used herein is used synonymously with the term “including” and variations thereof and are open, non-limiting terms. Although the terms “comprising” and “including” have been used herein to describe various embodiments, the terms “consisting essentially of” and “consisting of” can be used in place of “comprising” and “including” to provide for more specific embodiments of the invention and are also disclosed.

Other than where noted, all numbers expressing geometries, dimensions, and so forth used in the specification and claims are to be understood at the very least, and not as an attempt to limit the application of the doctrine of equivalents to the scope of the claims, to be construed in light of the number of significant digits and ordinary rounding approaches.

- 5 Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of skill in the art to which the disclosed invention belongs. Publications cited herein and the materials for which they are cited are specifically incorporated by reference.

WHAT IS CLAIMED IS:

1. A compound defined by Formula I



Formula I

or a pharmaceutically acceptable salt or prodrug thereof, wherein

X is chosen from O and S;

R¹, R², R³, R⁴, and R⁵ are each independently chosen from hydrogen, halogen, hydroxyl, -CN, -NO₂, amino, alkylamino, dialkylamino, alkyl, haloalkyl, alkylthio, haloalkylthio, alkoxy, haloalkoxy, alkenyl, haloalkenyl, alkynyl, haloalkynyl, alkylsulfinyl, haloalkylsulfinyl, alkylsulfonyl, haloalkylsulfonyl, alkylcarbonyl, haloalkylcarbonyl, alkoxycarbonyl, haloalkoxycarbonyl, alkylaminocarbonyl, heteroalkylaminocarbonyl, dialkylaminocarbonyl, and heterodialkylaminocarbonyl;

R⁶ and R⁷ are each independently chosen from hydrogen, hydroxy, halogen, -CN, -NO₂, amino, alkylamino, dialkylamino, alkyl, haloalkyl, alkylthio, haloalkylthio, alkoxy, haloalkoxy, alkenyl, haloalkenyl, alkynyl, haloalkynyl, alkylsulfinyl, haloalkylsulfinyl, alkylsulfonyl, haloalkylsulfonyl, alkylcarbonyl, haloalkylcarbonyl, alkoxycarbonyl, haloalkoxycarbonyl, alkylaminocarbonyl, heteroalkylaminocarbonyl, dialkylaminocarbonyl, and heterodialkylaminocarbonyl;

R⁸ is chosen from alkylamino, dialkylamino, alkyl, haloalkyl, alkylthio, haloalkylthio, alkoxy, haloalkoxy, alkenyl, haloalkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, cycloheteroalkyl, alkylaryl, alkylheteroaryl, alkylcycloalkyl, alkylcycloheteroalkyl, haloalkynyl, alkylsulfinyl, haloalkylsulfinyl, alkylsulfonyl, haloalkylsulfonyl, alkylcarbonyl, haloalkylcarbonyl, alkoxycarbonyl, haloalkoxycarbonyl, alkylaminocarbonyl, heteroalkylaminocarbonyl, dialkylaminocarbonyl, and heterodialkylaminocarbonyl, each optionally substituted with one or more substituents individually chosen from R¹¹;


R⁹ is chosen from hydrogen, hydroxy, halogen, -CN, -NO₂, amino, alkylamino, dialkylamino, alkyl, haloalkyl, alkylthio, haloalkylthio, alkoxy, haloalkoxy, alkenyl, haloalkenyl, alkynyl, haloalkynyl, aryl, heteroaryl, cycloalkyl, cycloheteroalkyl, alkylaryl, alkylheteroaryl, alkylcycloalkyl, alkylcycloheteroalkyl, alkylsulfinyl, haloalkylsulfinyl, alkylsulfonyl, haloalkylsulfonyl, alkylcarbonyl, haloalkylcarbonyl, alkoxycarbonyl, haloalkoxycarbonyl,

alkylaminocarbonyl, heteroalkylaminocarbonyl, dialkylaminocarbonyl, and heterodialkylaminocarbonyl, each optionally substituted with one or more substituents individually chosen from R^{11} ;

R^{10} is chosen from hydrogen, alkyl, haloalkyl, alkylthio, haloalkylthio, alkenyl, haloalkenyl, alkynyl, haloalkynyl, aryl, heteroaryl, cycloalkyl, cycloheteroalkyl, alkylaryl, alkylheteroaryl, alkylcycloalkyl, and alkylcycloheteroalkyl, each optionally substituted with one or more substituents individually chosen from R^{11} ; and

R^{11} is chosen from hydroxy, halogen, -CN, -NO₂, amino, alkylamino, dialkylamino, alkyl, haloalkyl; alkylthio; haloalkylthio; alkoxy, haloalkoxy, alkenyl, haloalkenyl, alkynyl, haloalkynyl, alkylsulfinyl, haloalkylsulfinyl, alkylsulfonyl, haloalkylsulfonyl, alkylcarbonyl, haloalkylcarbonyl, alkoxy carbonyl, haloalkoxy carbonyl, alkylaminocarbonyl, heteroalkylaminocarbonyl, dialkylaminocarbonyl, and heterodialkylaminocarbonyl;

with the proviso that the compound is not one of the following:




2. The compound of any of the preceding claims, wherein at least one of R^1 , R^2 , R^3 , R^4 , and R^5 is not hydrogen.

3. The compound of any of the preceding claims, wherein R^1 , R^2 , R^4 , and R^5 are hydrogen.

4. The compound of any of the preceding claims, wherein R^3 is an electron withdrawing group.
5. The compound of any of the preceding claims, wherein R^3 is haloalkyl.
6. The compound of any of the preceding claims, wherein R^3 is perfluoroalkyl.
7. The compound of any of the preceding claims, wherein R^3 is $-CF_3$.
8. The compound of any of the preceding claims, wherein at least one of R^6 and R^7 is not hydrogen.
9. The compound of any of the preceding claims, wherein at least one of R^6 and R^7 is halogen.
10. The compound of any of the preceding claims, wherein at least one of R^6 and R^7 is $-Cl$.
11. The compound of any of the preceding claims, wherein at least one of R^6 and R^7 is $-F$.
12. The compound of any of the preceding claims, wherein both R^6 and R^7 are not hydrogen.
13. The compound of any of the preceding claims, wherein both R^6 and R^7 are halogen.
14. The compound of any of claims 1-13, wherein both R^6 and R^7 are $-Cl$.
15. The compound of any of claims 1-13, wherein both R^6 and R^7 are $-F$.
16. The compound of any of the preceding claims, wherein R^8 comprises from 5 to 12 carbon atoms.
17. The compound of any of the preceding claims, wherein R^8 is chosen from alkyl, aryl, heteroaryl, alkylaryl, and alkylheteroaryl.

18. The compound of claim 17, wherein R^8 comprises a C_1 - C_8 alkyl group.
19. The compound of claim 18, wherein R^8 comprises a C_5 - C_8 alkyl group.
20. The compound of claim 17, wherein R^8 comprises a C_6 - C_{10} alkylaryl group.
21. The compound of claim 20, wherein R^8 comprises a substituted or unsubstituted benzyl group.
22. The compound of any of the preceding claims, wherein X is O.
23. The compound of any of claims 1-22, wherein R^9 is hydrogen.
24. The compound of any of claims 1-22, wherein R^9 comprises a C_1 - C_4 alkyl group or a phenyl group.
25. The compound of any of claims 1-24, wherein R^{10} is hydrogen.
26. The compound of any of claims 1-24, wherein R^{10} is chosen from alkyl, aryl, and alkylaryl.
27. The compound of claim 26, wherein R^{10} comprises a C_1 - C_4 alkyl group or a phenyl group.
28. The compound of any of the preceding claims, wherein the compound is defined by Formula II



Formula II

or a pharmaceutically acceptable salt or prodrug thereof, wherein


R^3 comprises an electron withdrawing group;

R^6 and R^7 are each independently chosen from hydrogen and halogen, with the proviso that at least one of R^6 and R^7 is halogen;

R^8 is chosen from alkyl, haloalkyl, alkoxy, haloalkoxy, alkenyl, haloalkenyl, alkynyl, haloalkynyl, aryl, heteroaryl, cycloalkyl, cycloheteroalkyl, alkylaryl, alkylheteroaryl, alkylcycloalkyl, alkylcycloheteroalkyl, each optionally substituted with one or more substituents individually chosen from R^{11} ; and

R^{11} is chosen from hydroxy, halogen, -CN, -NO₂, amino, alkylamino, dialkylamino, alkyl, haloalkyl; alkylthio; haloalkylthio; alkoxy, haloalkoxy, alkenyl, haloalkenyl, alkynyl, haloalkynyl, alkylsulfinyl, haloalkylsulfinyl, alkylsulfonyl, haloalkylsulfonyl, alkylcarbonyl, haloalkylcarbonyl, alkoxycarbonyl, haloalkoxycarbonyl, alkylaminocarbonyl, heteroalkylaminocarbonyl, dialkylaminocarbonyl, and heterodialkylaminocarbonyl;

with the proviso that the compound is not one of the following:



29. The compound of claim 28, wherein R^3 is chosen from halogen, -CN, -NO₂, haloalkyl, alkylcarbonyl, haloalkylcarbonyl, alkoxycarbonyl, and haloalkoxycarbonyl.


30. A biofilm preventing, removing, or inhibiting composition comprising a carrier and an effective amount of a compound defined by any of claims 1-29.

31. The composition of claim 30, wherein the composition is a dentifrice composition that promotes dental hygiene by preventing, reducing, inhibiting or removing a biofilm.

32. The composition of claim 31, wherein the dentifrice composition comprises a toothpaste, mouthwash, chewing gum, dental floss, or dental cream.

33. A composition comprising a compound defined by any of claims 1-29 in a pharmaceutically acceptable carrier.

34. A method of controlling biofilm formation on a substrate comprising contacting the substrate with a compound defined by Formula I



Formula I

or a pharmaceutically acceptable salt or prodrug thereof in an amount effective to inhibit biofilm formation, wherein

X is chosen from O and S;

R¹, R², R³, R⁴, and R⁵ are each independently chosen from hydrogen, halogen, hydroxyl, -CN, -NO₂, amino, alkylamino, dialkylamino, alkyl, haloalkyl, alkylthio, haloalkylthio, alkoxy, haloalkoxy, alkenyl, haloalkenyl, alkynyl, haloalkynyl, alkylsulfinyl, haloalkylsulfinyl, alkylsulfonyl, haloalkylsulfonyl, alkylcarbonyl, haloalkylcarbonyl, alkoxycarbonyl, haloalkoxycarbonyl, alkylaminocarbonyl, heteroalkylaminocarbonyl, dialkylaminocarbonyl, and heterodialkylaminocarbonyl;

R⁶ and R⁷ are each independently chosen from hydrogen, hydroxy, halogen, -CN, -NO₂, amino, alkylamino, dialkylamino, alkyl, haloalkyl, alkylthio, haloalkylthio, alkoxy, haloalkoxy, alkenyl, haloalkenyl, alkynyl, haloalkynyl, alkylsulfinyl, haloalkylsulfinyl, alkylsulfonyl, haloalkylsulfonyl, alkylcarbonyl, haloalkylcarbonyl, alkoxycarbonyl, haloalkoxycarbonyl, alkylaminocarbonyl, heteroalkylaminocarbonyl, dialkylaminocarbonyl, and heterodialkylaminocarbonyl;

R⁸ is chosen from alkylamino, dialkylamino, alkyl, haloalkyl, alkylthio, haloalkylthio, alkoxy, haloalkoxy, alkenyl, haloalkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, cycloheteroalkyl, alkylaryl, alkylheteroaryl, alkylcycloalkyl, alkylcycloheteroalkyl, haloalkynyl, alkylsulfinyl, haloalkylsulfinyl, alkylsulfonyl, haloalkylsulfonyl, alkylcarbonyl, haloalkylcarbonyl, alkoxycarbonyl, haloalkoxycarbonyl, alkylaminocarbonyl, heteroalkylaminocarbonyl, dialkylaminocarbonyl, and heterodialkylaminocarbonyl, each optionally substituted with one or more substituents individually chosen from R¹¹;

R⁹ is chosen from hydrogen, hydroxy, halogen, -CN, -NO₂, amino, alkylamino, dialkylamino, alkyl, haloalkyl, alkylthio, haloalkylthio, alkoxy, haloalkoxy, alkenyl, haloalkenyl,

alkynyl, haloalkynyl, aryl, heteroaryl, cycloalkyl, cycloheteroalkyl, alkylaryl, alkylheteroaryl, alkylcycloalkyl, alkylcycloheteroalkyl, alkylsulfinyl, haloalkylsulfinyl, alkylsulfonyl, haloalkylsulfonyl, alkylcarbonyl, haloalkylcarbonyl, alkoxycarbonyl, haloalkoxycarbonyl, alkylaminocarbonyl, heteroalkylaminocarbonyl, dialkylaminocarbonyl, and heterodialkylaminocarbonyl, each optionally substituted with one or more substituents individually chosen from R¹¹;

R¹⁰ is chosen from hydrogen, alkyl, haloalkyl, alkylthio, haloalkylthio, alkenyl, haloalkenyl, alkynyl, haloalkynyl, aryl, heteroaryl, cycloalkyl, cycloheteroalkyl, alkylaryl, alkylheteroaryl, alkylcycloalkyl, and alkylcycloheteroalkyl, each optionally substituted with one or more substituents individually chosen from R¹¹; and

R¹¹ is chosen from hydroxy, halogen, -CN, -NO₂, amino, alkylamino, dialkylamino, alkyl, haloalkyl; alkylthio; haloalkylthio; alkoxy, haloalkoxy, alkenyl, haloalkenyl, alkynyl, haloalkynyl, alkylsulfinyl, haloalkylsulfinyl, alkylsulfonyl, haloalkylsulfonyl, alkylcarbonyl, haloalkylcarbonyl, alkoxycarbonyl, haloalkoxycarbonyl, alkylaminocarbonyl, heteroalkylaminocarbonyl, dialkylaminocarbonyl, and heterodialkylaminocarbonyl.


35. The method of claim 34, wherein the compound defined by Formula I comprises a compound defined by any of claims 1-29

36. The method of any of claims 34-35, wherein the biofilm comprises Gram-positive bacteria.

37. The method of claim 36, wherein the biofilm comprises bacteria of a genus *Staphylococcus*.

38. The method of claim 37, wherein the biofilm comprises bacteria of the species *Staphylococcus aureus*.

39. A method for treating a chronic bacterial infection in a subject in need thereof, comprising administering to said subject a compound defined by Formula I



Formula I

or a pharmaceutically acceptable salt or prodrug thereof in an amount effective to inhibit, reduce, or remove a biofilm component of the chronic bacterial infection, wherein

X is chosen from O and S;

R¹, R², R³, R⁴, and R⁵ are each independently chosen from hydrogen, halogen, hydroxyl, -CN, -NO₂, amino, alkylamino, dialkylamino, alkyl, haloalkyl, alkylthio, haloalkylthio, alkoxy, haloalkoxy, alkenyl, haloalkenyl, alkynyl, haloalkynyl, alkylsulfinyl, haloalkylsulfinyl, alkylsulfonyl, haloalkylsulfonyl, alkylcarbonyl, haloalkylcarbonyl, alkoxycarbonyl, haloalkoxycarbonyl, alkylaminocarbonyl, heteroalkylaminocarbonyl, dialkylaminocarbonyl, and heterodialkylaminocarbonyl;

R⁶ and R⁷ are each independently chosen from hydrogen, hydroxy, halogen, -CN, -NO₂, amino, alkylamino, dialkylamino, alkyl, haloalkyl, alkylthio, haloalkylthio, alkoxy, haloalkoxy, alkenyl, haloalkenyl, alkynyl, haloalkynyl, alkylsulfinyl, haloalkylsulfinyl, alkylsulfonyl, haloalkylsulfonyl, alkylcarbonyl, haloalkylcarbonyl, alkoxycarbonyl, haloalkoxycarbonyl, alkylaminocarbonyl, heteroalkylaminocarbonyl, dialkylaminocarbonyl, and heterodialkylaminocarbonyl;

R⁸ is chosen from alkylamino, dialkylamino, alkyl, haloalkyl, alkylthio, haloalkylthio, alkoxy, haloalkoxy, alkenyl, haloalkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, cycloheteroalkyl, alkylaryl, alkylheteroaryl, alkylcycloalkyl, alkylcycloheteroalkyl, haloalkynyl, alkylsulfinyl, haloalkylsulfinyl, alkylsulfonyl, haloalkylsulfonyl, alkylcarbonyl, haloalkylcarbonyl, alkoxycarbonyl, haloalkoxycarbonyl, alkylaminocarbonyl, heteroalkylaminocarbonyl, dialkylaminocarbonyl, and heterodialkylaminocarbonyl, each optionally substituted with one or more substituents individually chosen from R¹¹;

R⁹ is chosen from hydrogen, hydroxy, halogen, -CN, -NO₂, amino, alkylamino, dialkylamino, alkyl, haloalkyl, alkylthio, haloalkylthio, alkoxy, haloalkoxy, alkenyl, haloalkenyl, alkynyl, haloalkynyl, aryl, heteroaryl, cycloalkyl, cycloheteroalkyl, alkylaryl, alkylheteroaryl, alkylcycloalkyl, alkylcycloheteroalkyl, alkylsulfinyl, haloalkylsulfinyl, alkylsulfonyl, haloalkylsulfonyl, alkylcarbonyl, haloalkylcarbonyl, alkoxycarbonyl, haloalkoxycarbonyl, alkylaminocarbonyl, heteroalkylaminocarbonyl, dialkylaminocarbonyl, and heterodialkylaminocarbonyl, each optionally substituted with one or more substituents individually chosen from R¹¹;

R¹⁰ is chosen from hydrogen, alkyl, haloalkyl, alkylthio, haloalkylthio, alkenyl, haloalkenyl, alkynyl, haloalkynyl, aryl, heteroaryl, cycloalkyl, cycloheteroalkyl, alkylaryl,

alkylheteroaryl, alkylcycloalkyl, and alkylcycloheteroalkyl, each optionally substituted with one or more substituents individually chosen from R¹¹; and

R¹¹ is chosen from hydroxy, halogen, -CN, -NO₂, amino, alkylamino, dialkylamino, alkyl, haloalkyl; alkylthio; haloalkylthio; alkoxy, haloalkoxy, alkenyl, haloalkenyl, alkynyl, haloalkynyl, alkylsulfinyl, haloalkylsulfinyl, alkylsulfonyl, haloalkylsulfonyl, alkylcarbonyl, haloalkylcarbonyl, alkoxycarbonyl, haloalkoxycarbonyl, alkylaminocarbonyl, heteroalkylaminocarbonyl, dialkylaminocarbonyl, and heterodialkylaminocarbonyl.


40. The method of claim 39, wherein the compound defined by Formula I comprises a compound defined by any of claims 1-29

41. The method of any of claims 39-40, wherein the chronic bacterial infection is chosen from urinary tract infection, gastritis, respiratory infection, cystitis, pyelonephritis, osteomyelitis, bacteremia, skin infection, rosacea, acne, chronic wound infection, infectious kidney stones, bacterial endocarditis, and sinus infection.

42. A medical device comprising:

(a) a medical device substrate; and

(b) an effective amount of a compound defined by Formula I



Formula I

or a pharmaceutically acceptable salt or prodrug thereof either coating the substrate, or incorporated into the substrate, wherein said effective amount of said compound prevents or inhibits the growth of a biofilm thereon, wherein

X is chosen from O and S;

R¹, R², R³, R⁴, and R⁵ are each independently chosen from hydrogen, halogen, hydroxyl, -CN, -NO₂, amino, alkylamino, dialkylamino, alkyl, haloalkyl, alkylthio, haloalkylthio, alkoxy, haloalkoxy, alkenyl, haloalkenyl, alkynyl, haloalkynyl, alkylsulfinyl, haloalkylsulfinyl, alkylsulfonyl, haloalkylsulfonyl, alkylcarbonyl, haloalkylcarbonyl, alkoxycarbonyl, haloalkoxycarbonyl, alkylaminocarbonyl, heteroalkylaminocarbonyl, dialkylaminocarbonyl, and heterodialkylaminocarbonyl;

R⁶ and R⁷ are each independently chosen from hydrogen, hydroxy, halogen, -CN, -NO₂, amino, alkylamino, dialkylamino, alkyl, haloalkyl, alkylthio, haloalkylthio, alkoxy, haloalkoxy, alkenyl, haloalkenyl, alkynyl, haloalkynyl, alkylsulfinyl, haloalkylsulfinyl, alkylsulfonyl, haloalkylsulfonyl, alkylcarbonyl, haloalkylcarbonyl, alkoxycarbonyl, haloalkoxycarbonyl, alkylaminocarbonyl, heteroalkylaminocarbonyl, dialkylaminocarbonyl, and heterodialkylaminocarbonyl;

R⁸ is chosen from alkylamino, dialkylamino, alkyl, haloalkyl, alkylthio, haloalkylthio, alkoxy, haloalkoxy, alkenyl, haloalkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, cycloheteroalkyl, alkylaryl, alkylheteroaryl, alkylcycloalkyl, alkylcycloheteroalkyl, haloalkynyl, alkylsulfinyl, haloalkylsulfinyl, alkylsulfonyl, haloalkylsulfonyl, alkylcarbonyl, haloalkylcarbonyl, alkoxycarbonyl, haloalkoxycarbonyl, alkylaminocarbonyl, heteroalkylaminocarbonyl, dialkylaminocarbonyl, and heterodialkylaminocarbonyl, each optionally substituted with one or more substituents individually chosen from R¹¹;

R⁹ is chosen from hydrogen, hydroxy, halogen, -CN, -NO₂, amino, alkylamino, dialkylamino, alkyl, haloalkyl, alkylthio, haloalkylthio, alkoxy, haloalkoxy, alkenyl, haloalkenyl, alkynyl, haloalkynyl, aryl, heteroaryl, cycloalkyl, cycloheteroalkyl, alkylaryl, alkylheteroaryl, alkylcycloalkyl, alkylcycloheteroalkyl, alkylsulfinyl, haloalkylsulfinyl, alkylsulfonyl, haloalkylsulfonyl, alkylcarbonyl, haloalkylcarbonyl, alkoxycarbonyl, haloalkoxycarbonyl, alkylaminocarbonyl, heteroalkylaminocarbonyl, dialkylaminocarbonyl, and heterodialkylaminocarbonyl, each optionally substituted with one or more substituents individually chosen from R¹¹;


R¹⁰ is chosen from hydrogen, alkyl, haloalkyl, alkylthio, haloalkylthio, alkenyl, haloalkenyl, alkynyl, haloalkynyl, aryl, heteroaryl, cycloalkyl, cycloheteroalkyl, alkylaryl, alkylheteroaryl, alkylcycloalkyl, and alkylcycloheteroalkyl, each optionally substituted with one or more substituents individually chosen from R¹¹; and

R¹¹ is chosen from hydroxy, halogen, -CN, -NO₂, amino, alkylamino, dialkylamino, alkyl, haloalkyl, alkylthio, haloalkylthio, alkoxy, haloalkoxy, alkenyl, haloalkenyl, alkynyl, haloalkynyl, alkylsulfinyl, haloalkylsulfinyl, alkylsulfonyl, haloalkylsulfonyl, alkylcarbonyl, haloalkylcarbonyl, alkoxycarbonyl, haloalkoxycarbonyl, alkylaminocarbonyl, heteroalkylaminocarbonyl, dialkylaminocarbonyl, and heterodialkylaminocarbonyl.

43. The medical device of claim 42, wherein the compound defined by Formula I comprises a compound defined by any of claims 1-29.

44. The medical device of any of claims 42-43, wherein the medical device substrate is chosen from stents, fasteners, ports, catheters, scaffolds and grafts.

45. A method of treating a subject infected with a bacterium comprising administering to the subject a therapeutically effective amount of a compound defined by Formula I



Formula I

or a pharmaceutically acceptable salt or prodrug thereof, wherein

X is chosen from O and S;

R¹, R², R³, R⁴, and R⁵ are each independently chosen from hydrogen, halogen, hydroxyl, -CN, -NO₂, amino, alkylamino, dialkylamino, alkyl, haloalkyl, alkylthio, haloalkylthio, alkoxy, haloalkoxy, alkenyl, haloalkenyl, alkynyl, haloalkynyl, alkylsulfinyl, haloalkylsulfinyl, alkylsulfonyl, haloalkylsulfonyl, alkylcarbonyl, haloalkylcarbonyl, alkoxycarbonyl, haloalkoxycarbonyl, alkylaminocarbonyl, heteroalkylaminocarbonyl, dialkylaminocarbonyl, and heterodialkylaminocarbonyl;

R⁶ and R⁷ are each independently chosen from hydrogen, hydroxy, halogen, -CN, -NO₂, amino, alkylamino, dialkylamino, alkyl, haloalkyl, alkylthio, haloalkylthio, alkoxy, haloalkoxy, alkenyl, haloalkenyl, alkynyl, haloalkynyl, alkylsulfinyl, haloalkylsulfinyl, alkylsulfonyl, haloalkylsulfonyl, alkylcarbonyl, haloalkylcarbonyl, alkoxycarbonyl, haloalkoxycarbonyl, alkylaminocarbonyl, heteroalkylaminocarbonyl, dialkylaminocarbonyl, and heterodialkylaminocarbonyl;

R⁸ is chosen from alkylamino, dialkylamino, alkyl, haloalkyl, alkylthio, haloalkylthio, alkoxy, haloalkoxy, alkenyl, haloalkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, cycloheteroalkyl, alkylaryl, alkylheteroaryl, alkylcycloalkyl, alkylcycloheteroalkyl, haloalkynyl, alkylsulfinyl, haloalkylsulfinyl, alkylsulfonyl, haloalkylsulfonyl, alkylcarbonyl, haloalkylcarbonyl, alkoxycarbonyl, haloalkoxycarbonyl, alkylaminocarbonyl, heteroalkylaminocarbonyl, dialkylaminocarbonyl, and heterodialkylaminocarbonyl, each optionally substituted with one or more substituents individually chosen from R¹¹;

R⁹ is chosen from hydrogen, hydroxy, halogen, -CN, -NO₂, amino, alkylamino, dialkylamino, alkyl, haloalkyl, alkylthio, haloalkylthio, alkoxy, haloalkoxy, alkenyl, haloalkenyl, alkynyl, haloalkynyl, aryl, heteroaryl, cycloalkyl, cycloheteroalkyl, alkylaryl, alkylheteroaryl,

alkylcycloalkyl, alkylcycloheteroalkyl, alkylsulfinyl, haloalkylsulfinyl, alkylsulfonyl, haloalkylsulfonyl, alkylcarbonyl, haloalkylcarbonyl, alkoxycarbonyl, haloalkoxycarbonyl, alkylaminocarbonyl, heteroalkylaminocarbonyl, dialkylaminocarbonyl, and heterodialkylaminocarbonyl, each optionally substituted with one or more substituents individually chosen from R¹¹;

R¹⁰ is chosen from hydrogen, alkyl, haloalkyl, alkylthio, haloalkylthio, alkenyl, haloalkenyl, alkynyl, haloalkynyl, aryl, heteroaryl, cycloalkyl, cycloheteroalkyl, alkylaryl, alkylheteroaryl, alkylcycloalkyl, and alkylcycloheteroalkyl, each optionally substituted with one or more substituents individually chosen from R¹¹; and

R¹¹ is chosen from hydroxy, halogen, -CN, -NO₂, amino, alkylamino, dialkylamino, alkyl, haloalkyl, alkylthio, haloalkylthio, alkoxy, haloalkoxy, alkenyl, haloalkenyl, alkynyl, haloalkynyl, alkylsulfinyl, haloalkylsulfinyl, alkylsulfonyl, haloalkylsulfonyl, alkylcarbonyl, haloalkylcarbonyl, alkoxycarbonyl, haloalkoxycarbonyl, alkylaminocarbonyl, heteroalkylaminocarbonyl, dialkylaminocarbonyl, and heterodialkylaminocarbonyl.

46. The method of claim 45, wherein the compound defined by Formula I comprises a compound defined by any of claims 1-29.

47. The method of any of claims 45-46, wherein the bacterium comprises a Gram-positive bacterium.

48. The method of claim 47, wherein the bacterium is chosen from *Staphylococcus aureus* (methicillin sensitive), *Staphylococcus aureus* (methicillin resistant), *Staphylococcus aureus* (vancomycin resistant), *Streptococcus pneumonia* (penicillin sensitive), *Streptococcus pneumonia* (penicillin resistant), *Staphylococcus epidermis* (multiple drug resistant), *Enterococcus faecalis* (vancomycin sensitive), *Enterococcus faecium* (vancomycin resistant), and *Haemophilus influenzae*.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 2017/048036

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☒ Claims Nos.: 4-27
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- ☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 2017/048036

A. CLASSIFICATION OF SUBJECT MATTER		C07D 263/40 (2006.01) C07D 263/46 (2006.01) A61K 31/421 (2006.01) A61P 31/04 (2006.01)																				
According to International Patent Classification (IPC) or to both national classification and IPC																						
B. FIELDS SEARCHED																						
Minimum documentation searched (classification system followed by classification symbols)																						
C07D 263/34, 263/40, 263/46, A61K 31/421, A61P 31/04																						
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched																						
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)																						
Esp@cenet, USPTO, RUPAT, PatSearch (RUPTO internal), PAJ, NCBI, DWPI																						
C. DOCUMENTS CONSIDERED TO BE RELEVANT																						
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.																				
X Y	SHYMANSKA N.V. et al. "Rapid synthesis and antimicrobial activity of novel 4-oxazolidinone heterocycles". BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2015, Vol.25, no.21, p.4887-4889. Retrieved from the Internet: http://dx.dpi.org/10.1016/j.bmcl.2015.06.0003 , pp.1-3, especially p.2, col.2, compounds in Table 4	1-3, 28-29, 39-41 45-48 42-44																				
X	US 5319100 A1 (SHIONOGI SEIYAKU KABUSHIKI KAISHA) 07.06.1994, abstract, col. 1, line 65-col. 2, lines 1-28, col.5, lines 60-63, col. 6, lines 3-12	1-3, 30-33																				
X Y	SHYMANSKA N.V et al. "A Rapid synthesis of 4-oxazolidinones: Total synthesis of synoxazolidinones A and B". ANGEWANDTE CHEMIE INTERNATIONAL EDITION, 2014, Vol.53, pp.1-5. DOI:10.1002/anie., especially p. 1, fig.1, Scheme 1, compound 6, p.2, Scheme 2, compound 10, Scheme 3	1-3, 39-41, 45-48 42-44																				
☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.																						
* Special categories of cited documents: <table border="0"> <tr> <td>"A"</td> <td>document defining the general state of the art which is not considered to be of particular relevance</td> <td>"T"</td> <td>later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</td> </tr> <tr> <td>"E"</td> <td>earlier document but published on or after the international filing date</td> <td>"X"</td> <td>document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</td> </tr> <tr> <td>"L"</td> <td>document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</td> <td>"Y"</td> <td>document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</td> </tr> <tr> <td>"O"</td> <td>document referring to an oral disclosure, use, exhibition or other means</td> <td>"&"</td> <td>document member of the same patent family</td> </tr> <tr> <td>"P"</td> <td>document published prior to the international filing date but later than the priority date claimed</td> <td></td> <td></td> </tr> </table>			"A"	document defining the general state of the art which is not considered to be of particular relevance	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	"E"	earlier document but published on or after the international filing date	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	"O"	document referring to an oral disclosure, use, exhibition or other means	"&"	document member of the same patent family	"P"	document published prior to the international filing date but later than the priority date claimed		
"A"	document defining the general state of the art which is not considered to be of particular relevance	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention																			
"E"	earlier document but published on or after the international filing date	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone																			
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art																			
"O"	document referring to an oral disclosure, use, exhibition or other means	"&"	document member of the same patent family																			
"P"	document published prior to the international filing date but later than the priority date claimed																					
Date of the actual completion of the international search		Date of mailing of the international search report																				
04 December 2017 (04.12.2017)		07 December 2017 (07.12.2017)																				
Name and mailing address of the ISA/RU: Federal Institute of Industrial Property, Berezhkovskaya nab., 30-1, Moscow, G-59, GSP-3, Russia, 125993 Facsimile No: (8-495) 531-63-18, (8-499) 243-33-37		Authorized officer M.Gorbatovskaya Telephone No. 495 531 65 15																				

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 2017/048036

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X Y	WO 2012/035305 A1 (LYTIX BIOPHARMA AS) 22.03.2012, p.3, line 14 - p.4, compounds A1 и C3, p.6, lines 6-29, p.7- 8, lines 23, examples, claims 1-5, 8-9, 11-14	34-41, 45-48 42-44